#ECC2015: We’re Going Digital

The ECCO App has proven itself with over 20,000 downloads to date. Download the latest interactive personalised Congress Programme to your device to achieve the most from #ECC2015

- Easily search and browse your tracks
- Access the latest about your sessions, presentations, posters, abstracts and exhibitors
- Create your personalised programme
- Find your way around
- And much, much more

www.europeancancercongress.org/app

Please note: no printed programme book will be provided at the Congress

The Organising Committee gratefully acknowledges the support and collaboration of all Member Societies of ECCO, the European CanCer organisation, without which this Congress would not be possible.

## Acknowledgements

**Founding Member**
- European Society for Medical Oncology (ESMO)
- European Society of Surgical Oncology (ESSO)
- European Society for Radiotherapy & Oncology (ESTRO)
- European Society of Paediatric Oncology (SIOPE)
- European Association of Nuclear Medicine (EANM)
- European Group for Blood and Marrow Transplantation (EBMT)
- Association of European Cancer Leagues (ECL)
- European Breast Cancer Coalition (EUROPA DONNA)
- European Prostate Cancer Coalition (EUROPA UOMO)
- European Association of Neuro-Oncology (EANO)
- European Association of Urology (EAU)
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Society of Gynaecological Oncology (ESGO)
- European School of Oncology (ESO)
- European Society of Oncology Pharmacy (ESOP)
- European Society of Breast Cancer Specialists (EUSOMA)
- European Society of Skin Cancer Prevention (EUROSKIN)

**Official Media Partners**

On behalf of the Executive Scientific Committee, we gratefully acknowledge the collaboration and support of our official media partners for the European Cancer Congress 2015.
Save the Dates

18th ECCO - 40th ESMO European Cancer Congress
25 – 29 September 2015

**Table of Contents**

- Acknowledgements
- Save the Dates
- Chairs’ Introduction
- European Cancer Congress 2015 Committees
- Opening Ceremony
- Programme at a Glance
- Detailed Advance Programme
- Young Oncologists @ ECC2015
- Patient Advocacy Track
- Oncopolicy Track
- Call for Abstracts
- Abstract Topic Categories
- Fellowship Grants and Educational Awards
- Why you should participate at ECC2015
- Digital Scientific Programme
- Registration
- Exhibition & Sponsorship
- General Information

**Save the Dates**

18th ECCO - 40th ESMO European Cancer Congress
25 – 29 September 2015

**KEY DATES AND DEADLINES**

<table>
<thead>
<tr>
<th>Event</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract submission opens</td>
<td>26 January 2015</td>
</tr>
<tr>
<td>Early rate registration deadline</td>
<td>9 April 2015</td>
</tr>
<tr>
<td>Abstract submission deadline</td>
<td>28 April 2015</td>
</tr>
<tr>
<td>Fellowship grant application deadline</td>
<td>29 April 2015</td>
</tr>
<tr>
<td>Late breaking abstract submission opens</td>
<td>22 July 2015</td>
</tr>
<tr>
<td>Regular rate registration deadline</td>
<td>4 August 2015</td>
</tr>
<tr>
<td>Late breaking abstract submission deadline</td>
<td>5 August 2015</td>
</tr>
<tr>
<td>Late rate registration deadline</td>
<td>18 September 2015</td>
</tr>
<tr>
<td>Congress in Vienna</td>
<td>25-29 September 2015</td>
</tr>
</tbody>
</table>

**Congress Venue**

Messe Wien Exhibition & Congress Centre

Messeplatz 1, 1021 Vienna, Austria
Detailed information about the venue:
www.messe.at/en

**Congress Secretariat**

c/o ECCO – the European CanCer Organisation
Avenue E. Mounier 83, B-1200 Brussels
Telephone: +32 (0)2 775 02 01
Fax: +32 (0)2 775 02 00
Email: ECC2015@ecco-org.eu

www.europeancancercongress.org
Chairs’ Introduction

The 18th ECCO – 40th ESMO European Cancer Congress (ECC2015) is the largest European multidisciplinary oncology platform for presenting ground-breaking data to a global audience this year.

We are on a path where each ECC Congress sets new records – increasing in the number of participants and submitted abstracts. The most recent ECC2013 in Amsterdam registered 16% growth in delegates and a massive 38% increase in the number of submitted abstracts compared to our event in Stockholm in 2011.

The European Cancer Congress is now giving fresh impetus to its unique philosophy of collaborative innovation to improve outcomes and find new solutions to pressing issues. Led by the ECC2015 Education Committee Chair, the educational programme is a result of the collaboration of all ECCO founding members, all experts in their respective fields. The programme is more streamlined, with fewer tracks, facilitating an even more productive experience for delegates. This Congress bridges basic and translational research to the clinic as research drives the change in how we treat our patients.

Topics of the greatest interest to a multidisciplinary audience will be presented by the very experts who will implement them. There are multidisciplinary tumour board sessions with a clinical orientation supported by case presentations. These sessions emulate multidisciplinary teams working in the real world and provide participants with concrete insights for immediate practical application. The scientific symposia will focus on the new developments in research and treatment that will impact the future of cancer diagnosis and care. ECC2015 will expand the much needed dialogue between basic and clinical researchers as well as the one between pathologists, molecular imaging specialists and clinicians whenever possible. The educational symposia and teaching lectures will provide state-of-the-art training in the most relevant topics in oncology at this time. The Oxford style debates are designed to shed light on the controversial topics impacting an oncologist's practice today.

The ECC programme also includes a track dedicated to public policy in cancer control. The Oncopolicy Forum harnesses the expertise and experience of the entire oncology community to bridge the gap between science and policy, and maximise the potential for achieving positive policy development with patient interests at the core.

The patient perspective is at the heart of the programme and of our collaborative innovation philosophy aimed at improving outcomes and including patients in identifying breakthrough solutions. The patient voice is now even more present in scientific sessions and delivers essential understanding enabling us to learn and to provide the best possible treatment and care.

Following its record number of abstract submissions in previous congresses, ECC2015 is again opening for abstract submission in January with a deadline of 28 April 2015. Abstracts will be selected to populate the presidential and proffered paper sessions and the poster and poster discussion sessions.

Each poster session is a must-attend event with over 3000 participants viewing the posters. This year, we will host “Posters in the spotlight” where selected authors will present their data during the poster sessions. This unique viewing will take place in the poster area.

And finally our late-breaking submission policy is specially designed to ensure the Congress embraces all promising new developments to ensure a very advanced, forward-looking scientific programme.

An application has been made to the EACCME® for CME accreditation of this event.

We have enriched the programme with new elements over and above those of CME – there are unique mentorship opportunities, a special leadership programme, and a number of targeted sessions offering insights into important areas of professional development for oncologists.

ECC2015 is a unique multidisciplinary Congress with a programme looking to the future through education, research and development, changing the landscape of oncology to improve the quality of treatment and care of cancer patients.

You may now browse the details of the scientific programme for the hot topics which will be presented by leading experts in each of our 27 tracks and for all the integrated sessions making the most of promising connections in research and clinical practice.

We are confident that you will discover much to interest you and we look forward to seeing you in Vienna in September!

Martine Piccart, Congress Chair, ECCO President
Rolf A. Stahel, ESMO President
Peter Naredi, ECCO Scientific Co-Chair
Elsabeth De Vries, ESMO Scientific Co-Chair
Jean-Yves Douillard, ECC2015 Education Committee Chair
Christoph Zielinski, National Organising Committee Chair
### European Cancer Congress 2015 Committees

#### Organising Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Piccart</td>
<td>Congress Chair, ECCO President</td>
</tr>
<tr>
<td>Rolf A. Stahel</td>
<td>ESMO President</td>
</tr>
<tr>
<td>Peter Naredi</td>
<td>ECCO Scientific Co-Chair</td>
</tr>
<tr>
<td>Elisabeth De Vries</td>
<td>ESMO Scientific Co-Chair</td>
</tr>
<tr>
<td>Christoph Zielinski</td>
<td>National Organising Committee Chair</td>
</tr>
<tr>
<td>Wim J.G. Oyen</td>
<td>ECCO Treasurer</td>
</tr>
</tbody>
</table>

#### Executive Scientific Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Naredi</td>
<td>ECCO Scientific Co-Chair</td>
</tr>
<tr>
<td>Elisabeth De Vries</td>
<td>ESMO Scientific Co-Chair</td>
</tr>
<tr>
<td>Philip Poortmans</td>
<td>Radiation Oncology Vice Chair</td>
</tr>
<tr>
<td>Richard Marais</td>
<td>Basic Science Vice Chair</td>
</tr>
<tr>
<td>Martine Piccart</td>
<td>Congress Chair, ECCO President</td>
</tr>
<tr>
<td>Rolf A. Stahel</td>
<td>ESMO President</td>
</tr>
<tr>
<td>Jean-Yves Douillard</td>
<td>ECC2015 Education Committee Chair</td>
</tr>
<tr>
<td>Christoph Zielinski</td>
<td>National Organising Committee Chair</td>
</tr>
</tbody>
</table>

#### Education Committee

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean-Yves Douillard</td>
</tr>
<tr>
<td>Andrés Cervantes</td>
</tr>
<tr>
<td>Nikolaos Pavlidis</td>
</tr>
<tr>
<td>Michele Chielmini</td>
</tr>
<tr>
<td>Giampaolo Tortora</td>
</tr>
<tr>
<td>Raffaele Califano</td>
</tr>
<tr>
<td>Claus-Henning Koehne</td>
</tr>
<tr>
<td>Robert Eckert</td>
</tr>
<tr>
<td>Florian Strasser</td>
</tr>
<tr>
<td>Richard Herrmann</td>
</tr>
<tr>
<td>Lorenz Jost</td>
</tr>
<tr>
<td>Karin Haustermans</td>
</tr>
<tr>
<td>Linda Wyld</td>
</tr>
<tr>
<td>Verena Jendrossek</td>
</tr>
<tr>
<td>Riccardo Riccardi</td>
</tr>
</tbody>
</table>

#### National Organising Committee

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christoph C. Zielinski</td>
</tr>
<tr>
<td>Walter Berger</td>
</tr>
<tr>
<td>Günter Gastl</td>
</tr>
<tr>
<td>Michael Gnant</td>
</tr>
<tr>
<td>Richard Greil</td>
</tr>
<tr>
<td>Wolfgang Hofer</td>
</tr>
<tr>
<td>Lukas A. Huber</td>
</tr>
<tr>
<td>Ulrich Jäger</td>
</tr>
<tr>
<td>Karin Kapp</td>
</tr>
<tr>
<td>Walter Klepetko</td>
</tr>
<tr>
<td>Ruth Ladenstein</td>
</tr>
<tr>
<td>Peter H. Lukas</td>
</tr>
<tr>
<td>Richard Pötter</td>
</tr>
<tr>
<td>Maria Sabilia</td>
</tr>
<tr>
<td>Hellmut Samonigg</td>
</tr>
<tr>
<td>Martin Schindl</td>
</tr>
<tr>
<td>Sebastian Schoppmann</td>
</tr>
<tr>
<td>Felix Sedlmayer</td>
</tr>
<tr>
<td>Veronika Sexl</td>
</tr>
<tr>
<td>Harald Titzer</td>
</tr>
</tbody>
</table>

Names in blue denote Chairs
The Opening Ceremony for the European Cancer Congress will take place on Friday 25 September from 19:25 in the Congress Centre.

The keynote speech will be given by Margaret Foti, PhD, MD (hc), Chief Executive Officer of AACR and Secretary-Treasurer of the AACR Foundation. She earned a master’s degree and a doctorate in communications from Temple University in Philadelphia, Pennsylvania. At the AACR, Margaret Foti worked collaboratively with its elected officers to provide the corporate knowledge and continuity of leadership that have been critical to the association’s progress and its mission to prevent and cure cancer. During Foti’s tenure, the AACR’s membership has grown from about 3,000 to 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 97 countries. Margaret Foti has since launched seven major peer-reviewed scientific journals: Cancer Epidemiology, Biomarkers & Prevention; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Prevention Research; Cancer Discovery; and Cancer Immunology Research. Dr Foti also leads the AACR’s scientific partnership with Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. Dr Foti is the recipient of many national and international awards for her contributions to cancer research including the European CanCer Organisation Lifetime Achievement Award.

Dr Foti will deliver a lecture focusing on “New Funding Models for Accelerating Progress Against Cancer”.

The Opening Ceremony will also feature an inspiring talk on science and music. As is customary, the National Organising Committee will introduce Vienna and Austria to the Congress participants. Prof. Dr. Klaus Laczika will present a “History of the Viennese Waltz - The Complexity of Ease - How did it all start, how did it evolve and where has it lead us?”

Following the ceremony, there will be a Networking Reception - an opportunity for Society Members and all experts participating in the Congress to meet and begin their exchange of ideas and thoughts on the latest achievements in research laboratories and clinical environments.
Programme at a Glance

Legend

<table>
<thead>
<tr>
<th>Organ Sites</th>
<th>Tracks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast Cancer - Advanced Disease</td>
<td>Innovations in Radiation Oncology</td>
</tr>
<tr>
<td>Breast Cancer - Early Disease</td>
<td>Paediatric Oncology</td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>Surgical Oncology</td>
</tr>
<tr>
<td>Gastrointestinal Malignancies - Colorectal Cancer</td>
<td>Young Oncologists</td>
</tr>
<tr>
<td>Gastrointestinal Malignancies - Noncolorectal Cancer</td>
<td></td>
</tr>
<tr>
<td>Genitourinary Malignancies - Nonprostate Cancer</td>
<td></td>
</tr>
<tr>
<td>Genitourinary Malignancies - Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>Gynaecological Cancer</td>
<td></td>
</tr>
<tr>
<td>Haematological Malignancies</td>
<td></td>
</tr>
<tr>
<td>Head and Neck Cancer</td>
<td></td>
</tr>
<tr>
<td>Lung Cancer - Localised/Regional Disease</td>
<td></td>
</tr>
<tr>
<td>Lung Cancer - Metastatic Disease</td>
<td></td>
</tr>
<tr>
<td>Melanoma and Skin Cancer</td>
<td></td>
</tr>
<tr>
<td>Nursing and Supportive Care</td>
<td>Oncology Nursing</td>
</tr>
<tr>
<td>Integrated Sessions</td>
<td>Supportive Care and Palliation</td>
</tr>
<tr>
<td>Immunotherapy of Cancer</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>Nursing and Supportive Care</td>
<td></td>
</tr>
<tr>
<td>Oncology Nursing</td>
<td></td>
</tr>
<tr>
<td>Supportive Care and Palliation</td>
<td></td>
</tr>
<tr>
<td>Integrated Sessions</td>
<td></td>
</tr>
<tr>
<td>Research and Drug Development</td>
<td>Basic Science/Translational Research</td>
</tr>
<tr>
<td>Clinical Trial Design and Regulatory Affairs</td>
<td></td>
</tr>
<tr>
<td>Early Drug Development</td>
<td></td>
</tr>
<tr>
<td>Patient Advocacy and Policy</td>
<td>Cancer Prevention and Screening</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td></td>
</tr>
<tr>
<td>General</td>
<td></td>
</tr>
<tr>
<td>Industry</td>
<td></td>
</tr>
<tr>
<td>Non CME</td>
<td></td>
</tr>
</tbody>
</table>

Opening Ceremony 19:15 - 21:00
### Monday, 28 September 2015

#### Programme:

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>09:00-11:15</td>
<td>Image Guided How to Stage and Peritoneal Surface Dose and Volume Testing Supportive Treat Hodgkin a Late Effect in Malignancies Using Neuro-Oncology: Care Interventions</td>
</tr>
<tr>
<td>11:00</td>
<td>11:00-13:00</td>
<td>New Drugs on the Era of PET Cancer?</td>
</tr>
<tr>
<td>13:00</td>
<td>13:00-15:00</td>
<td>This House Believes The Quality of the Right Surgery Stalling?</td>
</tr>
<tr>
<td>15:00</td>
<td>15:00-17:00</td>
<td>This House Believes that Surgery High Risk and Prognosis</td>
</tr>
</tbody>
</table>

### Cancer Care Congress 2015:

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>09:00-11:15</td>
<td>Image Guided How to Stage and Peritoneal Surface Dose and Volume Testing Supportive Treat Hodgkin a Late Effect in Malignancies Using Neuro-Oncology: Care Interventions</td>
</tr>
<tr>
<td>11:00</td>
<td>11:00-13:00</td>
<td>New Drugs on the Era of PET Cancer?</td>
</tr>
<tr>
<td>13:00</td>
<td>13:00-15:00</td>
<td>This House Believes The Quality of the Right Surgery Stalling?</td>
</tr>
<tr>
<td>15:00</td>
<td>15:00-17:00</td>
<td>This House Believes that Surgery High Risk and Prognosis</td>
</tr>
</tbody>
</table>

### ECCO 18 - ESMO 40 - European Cancer Congress - ADVANCE PROGRAMME

#### Tuesday, 29 September 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>09:00-11:15</td>
<td>Image Guided How to Stage and Peritoneal Surface Dose and Volume Testing Supportive Treat Hodgkin a Late Effect in Malignancies Using Neuro-Oncology: Care Interventions</td>
</tr>
<tr>
<td>11:00</td>
<td>11:00-13:00</td>
<td>New Drugs on the Era of PET Cancer?</td>
</tr>
<tr>
<td>13:00</td>
<td>13:00-15:00</td>
<td>This House Believes The Quality of the Right Surgery Stalling?</td>
</tr>
<tr>
<td>15:00</td>
<td>15:00-17:00</td>
<td>This House Believes that Surgery High Risk and Prognosis</td>
</tr>
</tbody>
</table>

---

*ECCO 18 - ESMO 40 - European Cancer Congress - ADVANCE PROGRAMME*
ECCO 18 - ESMO 40 - European Cancer Congress - ADVANCE PROGRAMME

Friday 25 September 2015

Opening Ceremony
09:15 - 11:00
New funding models for accelerating progress against cancer
Speaker: A. Falt (United States)
Details to be announced in the online searchable programme and final programme as soon as possible

Saturday 26 September 2015

Opening Plenary Session
08:45 - 10:15
Welcome by Congress President
Speaker: M. Piccirilli (Belgium)
Chair of ECOG Patient Advisory Committee
Panel I: Banks (Belgium)
EONS President
Panel: V. van Dijk (Netherlands)
EACR President
Panel: K. van den Muirkorn (Netherlands)
ESTRO President
Panel: P. Poortmans (Netherlands)
ESMO President
Panel: V. van den Muirkorn (Netherlands)
SIOPE President
Panel: C. Vassal (France)
SIOG President
Panel: R. Morris (United Kingdom)

Keynote Lecture
Speaker: To be announced

Details to be announced in the online searchable programme and final programme as soon as possible

Presidential Session I
12:45 - 14:30
Chair: C. Robert (France)
Immunotherapy, past, present and future
Speaker: L. Garraway (USA)

Special Session: EURECCA
12:45 - 14:30
Chair: C. Robert (France)
Immunotherapy, past, present and future
Speaker: L. Garraway (USA)

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO Clinical Practice Guidelines
09:15 - 11:15
Chair: A. Cervantes (Spain)
Co-Chair: G. Pantelidou (Greece)
Introduction to the ESMO Clinical Practice Guidelines
Speaker: A. Cervantes (Spain)

Questions & Answers

Multiple myeloma case presentation
Speaker: To be announced
Discussed: To be announced

Questions & Answers

Malnutrition/cachexia case presentation
Speaker: To be announced
Discussion: F. Peccatori (Italy)

Questions & Answers

Breast cancer case presentation: HER2+ metastatic disease after adjuvant trastuzumab
Speaker: E. van Dongen (Netherlands)
Discussion: E. Rosenthal (United States)

Questions & Answers

Breast cancer in Europe
Speaker: E. Boscharens (Netherlands)

Discussion

Special Session: Women in Oncology Forum
23:00 - 14:30
Details to be announced in the online searchable programme and final programme as soon as possible

Presidential Session II
14:45 - 16:45
Chair: E. Brain (France)
Operating the older patient: Yes, it is possible!
Speaker: R. Audisio (United Kingdom)

Questions & Answers

Multiple myeloma case presentation
Speaker: To be announced
Discussed: To be announced

Questions & Answers

Malnutrition/cachexia case presentation
Speaker: To be announced
Discussion: F. Peccatori (Italy)

Questions & Answers

Breast cancer case presentation: HER2+ metastatic disease after adjuvant trastuzumab
Speaker: E. van Dongen (Netherlands)
Discussion: E. Rosenthal (United States)

Questions & Answers

Breast cancer in Europe
Speaker: E. Boscharens (Netherlands)

Discussion

Special Session: ESMO Designated Centres of Integrated Oncology and Palliative Care
18:15 - 20:15
Chair: F. Stassier (Switzerland)

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Co-Founder Symposium: Genomic Oncology - A Multidisciplinary Approach to Reinforce Positive Outcomes in Older Patients
09:15 - 10:45
Chair: M. Aapro (Switzerland)
Chair: J. Brain (France)

A case among others in your MDT meeting: An 83 year old breast cancer patient
Presentation of the patient
Speaker: M. Aapro (Switzerland)
Operating the older patient: Yes, it is possible!
Speaker: R. Audisio (United Kingdom)

Chemo-Irradiate or not the older breast cancer patient
Speaker: H. Lüdtke (Germany)

But what about her quality of life?
Speaker: R. Britz (Spain)

The role of the geriatrician
Speaker: M. Runge (France)

Not competing but collaborating and final words
Speaker: E. Brain (France)

Questions & Answers

Scientific Symposium: ESMO/ESMO Co-Founder Symposium: Genomic Oncology - A Multidisciplinary Approach to Reinforce Positive Outcomes in Older Patients
11:30 - 12:30
Chair: J.C. Soria (France)

Discussion

Tuesday 27 September 2015

Highlight Session
08:00 - 08:45
Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ESMO/ESMO Co-Founder Symposium: Genomic Oncology - A Multidisciplinary Approach to Reinforce Positive Outcomes in Older Patients
09:15 - 10:45
Chair: M. Aapro (Switzerland)
Chair: J. Brain (France)

A case among others in your MDT meeting: An 83 year old breast cancer patient
Presentation of the patient
Speaker: M. Aapro (Switzerland)
Operating the older patient: Yes, it is possible!
Speaker: R. Audisio (United Kingdom)

Chemo-Irradiate or not the older breast cancer patient
Speaker: H. Lüdtke (Germany)

But what about her quality of life?
Speaker: R. Britz (Spain)

The role of the geriatrician
Speaker: M. Runge (France)

Not competing but collaborating and final words
Speaker: E. Brain (France)

Questions & Answers

Scientific Symposium: ESMO/ESMO Co-Founder Symposium: Genomic Oncology - A Multidisciplinary Approach to Reinforce Positive Outcomes in Older Patients
11:30 - 12:30
Chair: J.C. Soria (France)

Discussion

Scientific Symposium: ESMO/ESMO Co-Founder Symposium: Genomic Oncology - A Multidisciplinary Approach to Reinforce Positive Outcomes in Older Patients
13:00 - 14:30
Chair: J. Cara (France)

Academic perspective
Speaker: D. Solis (USA)

Industry perspective
Speaker: R. Raus (USA)

FDA perspective
Speaker: P. Cortazar (USA)

EMA perspective
Speaker: G. Alvarado (Spain)

Patient advocate perspective
Speaker: D. Ross (Switzerland)

Paediatric oncologist perspective
Speaker: R. Lammersen (Australia)

Discussion

Sunday 27 September 2015

Highlight Session
08:00 - 08:45
Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ASCO/ECCO Joint Symposium
14:45 - 16:45
Chair: F. Stassier (Switzerland)

Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ASCO/ECCO Joint Symposium
17:00 - 18:30
Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ASCO/ECCO Joint Symposium
18:45 - 20:15
Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ASCO/ECCO Joint Symposium
20:30 - 22:00
Details to be announced in the online searchable programme and final programme as soon as possible

Scientific Symposium: ASCO/ECCO Joint Symposium
22:15 - 00:45
Details to be announced in the online searchable programme and final programme as soon as possible
Tuesday 29 September 2015

Highlight Session
08:00-08:45
Details to be announced in the online searchable programme and final programme as soon as possible

INTEGRATED

Sunday 27 September 2015

Integrated Session: Treating Lymphoid Malignancies in Children and Adults with the Same Protocols
09:45 - 11:15
Chair: M. Pfundschuh (Germany)
Co-Chair: G. Mariani (Italy)

Introduction
Speaker: M. Pfundschuh (Germany)
Burkitt’s lymphoma in children
Speaker: V. Abreu-Cunha (France)
Burkitt’s lymphoma in adults
Speaker: I. Trumper (Germany)
Lymphoblastic leukaemia in children
Speaker: M. Neymen (Sweden)
Lymphoblastic leukaemia in adults
Speaker: B. Beisal (Israel)

Discussion & Roundup

Integrated Session: Integrating Carcinoma Care and Adolescent and Young Adult Cancer Care
09:45 - 11:15
Chair: M. Pfreundschuh (Germany)

Lymphoid Malignancies in Children
Integrated Session: Treating
09:00 - 11:00
Chair: A.F. Sobrero (Italy)
Co-Chair: S. Combs (Germany)
Introduction
Speaker: A.F. Sobrero (Italy)
Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Popat (United Kingdom)
Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Preusser (Austria)

Discussion & Roundup

Integrated Session: How to Personalise Treatment Modalities in Locally Advanced Rectal Cancer
16:45 - 18:45
Chair: A.F. Sobrero (Italy)
Co-Chair: S. Combs (Germany)

Response assessment in brain metastases
Speaker: M. Brada (United Kingdom)
Advances in loco-regional treatments
Speaker: M. Brada (United Kingdom)
Tolerability of brain metastasis treatments
Speaker: A. Soffietti (Italy)

Discussion & Roundup

Tuesday 29 September 2015

Integrated Session: Novel Approaches to Brain Metastases
09:45 - 11:15
Chair: S. Gamba (Germany)
Co-Chair: A. Enzi (Romania)

Biology of brain metastases
Speaker: P. Loening (USA)
Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Popat (United Kingdom)
Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Preusser (Austria)

Discussion & Roundup

Integrated Session: Young Adult Oncology
24:00 - 19:05
Chair: M. Pfreundschuh (Germany)

Burkitt’s lymphoma in adults
Speaker: A. Enzi (Romania)
Chemotherapy in Burkitt’s lymphoma
Speaker: A. Enzi (Romania)
Lymphoblastic leukaemia in children
Speaker: M. Neyman (Sweden)

Discussion & Roundup

Integrated Session: Metastatic Melanoma
24:00 - 19:05
Chair: S. Gamba (Germany)

Discussion & Roundup

Monday 28 September 2015

Integrated Session: Novel Approaches to Brain Metastases
09:45 - 11:15
Chair: S. Gamba (Germany)
Co-Chair: A. Enzi (Romania)

Biology of brain metastases
Speaker: P. Loening (USA)
Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Popat (United Kingdom)
Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Preusser (Austria)

Discussion & Roundup

Integrated Session: Immunotherapy in NSCLC - 2015
09:00 - 11:00
Chair: L. Paz-Ares (Spain)
Co-Chair: M. Reck (Germany)

Introduction
Speaker: L. Paz-Ares (Spain)
Lung cancer: An immunogenic tumour?
Speaker: A. Quirke (United Kingdom)
Any place for vaccination strategies?
Speaker: S. Wiertz (Belgium)

Discussion & Roundup
Scientific Symposium: Novel Approaches to Brain Metastases
10:45 - 11:30
Chair: S. Combs (Germany)
—
Co-Chair: A. Eniu (Romania)
Discussion & Roundup
Scientific Symposium: Novel Look on the Horizon II
17:00 - 18:30
Chair: F. Ciardiello (Italy)
—
Co-Chair: J. Stary (Czech Republic)
Discussion & Roundup
Scientific Symposium: Onco-Oncology of Gastro-Oesophageal Cancer: Implications for Treatment
11:30 - 12:30
Chair: J.C. Soria (France)
—
Roundtable: Oncology Drug Development in the Era of Genomic Sequencing
13:00 - 14:30
Chair: J. Gnan (France)
—
Academic perspective
Speaker: D. Solit (USA)
Industry perspective
Speaker: A. Riva (USA)
FDA perspective
Speaker: P. Corradini (Italy)
EMA perspective
Speaker: F. Pignatti (United Kingdom)
Patient advocate perspective
Speaker: S. Combs (Germany)
Paediatric oncologist perspective
Speaker: A. Thierry (France)
Discussion
Scientific Symposium: Mechanisms of Resistance to Targeted Therapies
17:00 - 18:30
Chair: R. Morais (United Kingdom)
Co-Chair: O. Schaidt (Germany)
BRAF signalling in melanoma
Speaker: R. Morais (United Kingdom)
Signalling networks and resistance
Speaker: D. Dunmur (Suriname)
Metabolism and resistance
Speaker: G. Proper (Netherlands)
Mechanisms and resistance
Speaker: C. Lung (Australia)
Discussion & Roundup

Scientific Symposium: Genetics of Resistance to Targeted Therapies
17:00 - 18:30
Chair: R. Carvao (Portugal)
Co-Chair: J. Van den Bulcke (Belgium)
Drug action on ovary cancer cells and tumour microenvironment
Speaker: D. Notarangelo (Italy)
Folate receptor blockers
Speaker: J. Verweij (Netherlands)
Treatment opportunities for homologous recombination deficiency
(PARP) inhibitors
Speaker: S. Borner (United Kingdom)
Immunotherapy opportunities in ovarian cancer
Speaker: C. Cavalet (Suriname)
Discussion & Roundup

Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics
17:00 - 18:30
Chair: S. Leclee (Belgium)
Co-Chair: L.L. Su (Canada)
Pharmacologic biomarkers in the development of stratified cancer medicine
Speaker: H. Neussel (United Kingdom)
One size doesn’t fit all - current status of commonly used surrogate markers across tumours: Paradigms from colorectal, lung and breast cancer
Speaker: M. Buys (Belgium)
Companion diagnostic co-development in personalised medicine including circulating tumour cells
Speaker: L.L. Su (Canada)
Is M0 a valid surrogate endpoint for evaluation of new drugs in lung cancer?
Speaker: M. Wibbeck (Italy)
Discussion & Roundup

Scientific Symposium: Immunotherapy in NSCLC - 2015
09:00 - 10:30
Chair: A. Colombo (Italy)
Co-Chair: S.A. Fuqua (USA)
Introduction to immunotherapy for lung cancer
Speaker: M.A. Giaccone (USA)
Immunogens and immunostimulatory monoclonal antibodies
Speaker: I. Akhurst (Spain)
Melanoma targeted therapies in the interface with immunotherapy
Speaker: A. Abbas (USA)
Virotherapy and immunotherapy
Speaker: A. Lechler (United Kingdom)
Discussion & Roundup

Scientific Symposium: High-Tech Innovations for Precision Radiation Oncology: Concept, Status and Clinical Benefit
09:00 - 10:30
Chair: P. Pratsmars (Netherlands)
Co-Chair: D. Georg (Austria)
How can protons contribute to radiation oncology
Speaker: M. Schulte (Germany)
Might it be heavier? Irradiation with carbon and other ions
Speaker: R. Brada (Italy)
Introduction
Speaker: J. Pras (Austria)
Lung cancer: An immunogenic tumour?
Speaker: S.A. Quaas (United Kingdom)
Any place for vaccination strategies?
Speaker: J. Van den Bulcke (Belgium)
Discussion & Roundup

Discussion & Roundup Tuesday 29 September 2015

Scientific Symposium: Optimal Treatment of LUMINAL Breast Cancer: Emerging Data on Improving Response to Hormone Therapy
09:00 - 10:30
Chair: M.A. Giaccone (Italy)
Co-Chair: S.A. Fuqua (USA)
How to optimise endocrine sequence in luminal breast cancer
Speaker: S.A. Fuqua (USA)
Introduction to mTOR and PI3K inhibitors
Speaker: M. Marion (Spain)
Genomics and responses to endocrine therapies
Speaker: M. Ellis (USA)
Role of cyclin-dependent kinase 4/6 inhibitors in endocrine therapy
Speaker: F. Cardoso (Portugal)
Discussion & Roundup

Integrated Session: Immunotherapy in the Management of Metastatic Melanoma
09:00 - 11:00
Chair: A.M.A. Eggermont (France)
Co-Chair: PA. Ascierto (Italy)
Introduction
Speaker: A.M.A. Eggermont (France)
Biomarkers for the complex biology of melanoma immunotherapy
Speaker: C. Robert (France)
Immunogens and immunostimulatory monoclonal antibodies
Speaker: I. Akhurst (Spain)
Melanoma targeted therapies in the interface with immunotherapy
Speaker: A. Abbas (USA)
Virotherapy and immunotherapy
Speaker: A. Lechler (United Kingdom)
Discussion & Roundup

Scientific Symposium: Mechanisms of Response to Targeted Therapies
11:15 - 12:15
Chair: D.R. Camidge (USA)
Co-Chair: N. Gough (Australia)
Robust endpoints when evaluating novel “targeted” therapies
Speaker: M. Valsecchi (Italy)
Discussion & Roundup

Panel Discussion

Breast Cancer: Emerging Data on Clinical Benefit
11:15 - 12:15
Chair: B. Escudier (France)
Co-Chair: M. Reck (Germany)
Therapy of luminal breast cancer: Emerging data on predicting clinical benefit
Speaker: M. Reck (Germany)
How to optimise endocrine sequence in luminal breast cancer
Speaker: M. Martin (Spain)
Discussion & Roundup

Discussion Panel: The Prerequisite for Ideal Biobanking
13:45 - 14:15
Chair: J. DiVer (Switzerland)
How much is important for the basic research the material and the dataset?
Speaker: F. Carneiro (Portugal)
From the operating room to the laboratory, the value of surgery standardisation and data collection in a tissue bank
Speaker: G. Carretta (Italy)
Interventional radiologist (please suggest your title)
Speaker: J. Futterer (Netherlands)
Discussion

Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics
17:00 - 18:30
Chair: R. Banterle (Germany)
Co-Chair: S. Popat (United Kingdom)
Targeted treatment in squamous cell lung cancer
Speaker: J. Veld (Germany)
EGFR Inhibition - current status and future perspectives
Speaker: A. Hsu (USA)
ALK Inhibition - current status and future perspectives
Speaker: A. Mihal (China)
BEYOND EGFR and ALK - future targets
Speaker: S. Peters (Switzerland)
Discussion & Roundup
Sunday 27 September 2015

Teaching Lecture: Recent Developments in the Treatment of Metastatic Breast Cancer: Translational Aspects
08:00 - 08:45
Chair: A. Di Leo (Italy)
Co-Chair: F. trương (Vietnam)

Multidisciplinary Tumour Board: Breast Cancer
11:30 - 12:30
Chair: P. Pauc (Netherlands)
Case presentation by young oncologist: Early disease
Speaker: I. Kieda (Belgium)
Panel Discussion: Early disease
Discussion & Roundup

Monday 28 September 2015

Integrated Session: Novel Approaches to Brain Metastases
09:45 - 11:15
Chair: S. Gomb (Germany)
Co-Chair: A. Enzi (Italy)

Biological of brain metastases
Speaker: F. S. Storo (USA)

Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Pados (United Kingdom)

Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Prusser (Austria)

Novel systemic therapy approaches to brain metastases: Melanoma
Speaker: A. Schindler (Germany)

Advances in loco-regional treatments
Speaker: M. Brüggen (United Kingdom)

Tolerability of brain metastasis treatments
Speaker: A. Soffritti (Italy)

Response assessment in brain metastases
Speaker: M. Lin (USA)

Discussion & Roundup

Society Session: European Society of Breast Cancer Specialists (EUSOMA)
09:15 - 11:15
Chair: M. Liden (Finland)
Chair: J. Rapal (United Kingdom)

Radiotherapy and DCIS
Speaker: C. Creutzig (United Kingdom)

What are the chemoprevention options for high-risk women?
Speaker: J. Castan (United Kingdom)

Treating positive nodes in the axilla
Speaker: C. M. Shepels (Spain)

How much oncoplastic surgery?
Speaker: R. M. Man (United Kingdom)
Should we tailor adjuvant therapy to specific sub-types?
Speaker: C. Aragonés (Italy)

Genetic counselling for women with DCIS and positive family history
Speaker: A. Bonanno (Italy)

Discussion

Debate: This House Believes That Mammographic Screening Should Be Discontinued
11:30 - 12:30
Moderator: M. S. Rossi (Italy)
Speaker 1: F. B. J. (Portugal)
Speaker 2: J. O. A. C. (Austria)
Speaker 3: G. C. E. (Netherlands)
Speaker 4: B. A. C. (New Zealand)

Role of cyclin-dependent kinase 4/6 inhibitors in endocrine therapy
Speaker: F. Cavali (Portugal)

Discussion & Voting

Scientific Symposium: New Techniques in Avoiding Overutilization in Early Breast Cancer
17:00 - 18:00
Chair: M. Liden (Finland)
Co-Chair: A. Di Leo (Italy)

Avoiding surgery in DCIS: How can we select low-risk disease
Speaker: A. F. F. J. K. (United Kingdom)

Minimising harm and maximising benefit with radiotherapy: New horizons
Speaker: C. O. Smith (United Kingdom)

Discussion & Roundup

Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer
17:00 - 18:30
Chair: A. Berges (Norway)
Co-Chair: C. Caldas (United Kingdom)

Inference of tumour evolution during chemotherapy
Speaker: S. A. Pariser (Canada)

Heterogeneity and treatment failure in HER2-positive breast cancers
Speaker: L. C. Bug (Canada)

Role of liquid vs solid biopsies in monitoring treatment
Speaker: C. Caldas (United Kingdom)

New frontiers in molecular imaging to improve targeting of high-risk disease
Speaker: C. De Vries (Netherlands)

Discussion & Roundup

Tuesday 29 September 2015

Teaching Lecture: Staging the Axilla: Imaging and Sentinel Node Technologies
08:00 - 08:45
Chair: L. Wyld (United Kingdom)
Speaker: F. Rubis (Spain)

Scientific Symposium: Optimal Treatment of Luminal Breast Cancer: Emerging Data on Improving Response to Hormone Therapy
09:00 - 10:30
Chair: M. Colleoni (Italy)
Co-Chair: A. F. F. J. K. (United Kingdom)

How to optimise endocrine sequence in luminal breast cancer
Speaker: J. A. P. F. W. (USA)

Introducing mTOR and PI3K inhibitors in endocrine therapy
Speaker: M. E. W. (USA)

Genomics and response to endocrine therapies
Speaker: M. E. W. (USA)

Role of cyclin-dependent kinase 4/6 inhibitors in endocrine therapy
Speaker: F. Cavali (Portugal)

Discussion & Roundup

Special Session: Management Strategies for Hereditary Gene Mutation Carriers with Early Breast Cancer
11:15 - 12:15
Chair: P. Pauc (Netherlands)

Expanding the range of gene testing as next generation sequencing enters clinical practice
Speaker: F. Fostira (Greece)

Surgical strategies for gene carriers: Breast conservation versus unilateral or bilateral mastectomy
Speaker: G. Colleoni (Italy)

Adjuvant systemic therapy: Could it be less intensive?
Speaker: M. C. Kelemen (Italy)

Tailoring chemotherapy for hereditary breast cancer carriers
Speaker: A. Tutt (United Kingdom)

Discussion

CANCER IN ELDERLY
Saturday 26 September 2015

Scientific Symposium: Managing Older People with Cancer and Other Co-Morbidities - An Increasing Challenge
10:45 - 10:30
Chair: M. Colleoni (Italy)
Co-Chair: J. Sharp (Scotland)

New models of follow-up for increasingly complex patient profiles
Speaker: C. Catani (Italy)

Meeting clinical care needs in the clinic. The example of polypharmacy
Speaker: A. Van den Bérate (Netherlands)

The importance of appropriate assessment for older people with cancer
Speaker: C. Karis (Belgium)

Being innovative to support older people with cancer in clinical settings
Speaker: J. H. H. (United Kingdom)

Discussion & Roundup

Monday 28 September 2015

Educational Symposium: Combined Modality Treatment in Elderly with Bladder Cancer
09:00 - 10:30
Chair: A. Tutt (United Kingdom)
Co-Chair: S. A. W. Fuqua (USA)

Combining modality treatment put into context for practice
Speaker: J. O. D. (France)

Discussion & Roundup

Special Session: The Right Surgery for the Right Patient: Predictions & Outcomes
15:30 - 16:15
Chair: T. Grabacki (Australia)

Selection for risk reduction surgery in hereditary syndromes
Speaker: A. A. A. (United Kingdom)

Individualisation of treatment for older cancer patients
Speaker: J. A. A. (United Kingdom)

Have guidelines improved outcomes or not?
Speaker: S. Sandrucci (Italy)

Discussion

Scientific Symposium: The Challenges of Treating the Older Patient with Upper GI Cancer
17:00 - 18:00
Chair: M. A. A. (Australia)
Co-Chair: D. P. (Canada)

Assessing patients for treatment
Speaker: S. W. (W. Australia)

The oncologist’s perspective
Speaker: S. J. (W. Australia)

Are you ever too old for complex upper GI surgery?
Speaker: W. A. (United Kingdom)

A radiotherapist perspective
Speaker: A. G. (Australia)

Discussion & Roundup
Tuesday 29 September 2015

Special Session: Clinical Challenges in Adjunct Therapy in Rectal and Colon Cancer
---
21:15 - 22:15
Chair: A. Cervantes (Spain)
Adjuvant therapy in rectal cancer
Speaker: K. Haustermans (Belgium)
Adjuvant therapy in the elderly
Speaker: D. Papamichael (Cyprus)
Adjuvant therapy in stage II colon cancer
Speaker: J. Tindle (France)
Discussion

CANCER PREVENTION AND SCREENING
Sunday 27 September 2015

Special Session: HPV Vaccine for Cancer Prevention
---
14:15 - 16:15
Chair: K. Soldan (United Kingdom)
Achieving high coverage of HPV vaccination
Speaker: X. Bosch (Spain)
Vaccination of boys/young males
Speaker: R. Herreman (France)
Preclinical vaccines
Speaker: C-M. Melief (Netherlands)
Discussion

CENTRAL NERVOUS SYSTEM
Saturday 26 September 2015

Society Session: European Association of Neuro-Oncology (EANO) - New Tools and Toys in Neuro-Oncology
---
20:30 - 22:30
Chair: R. Soffetti (Italy)
Co-Chair: S. Corbo (Germany)
EANO Award
Awardee: J-P. Gilbert (France)
Advanced molecular genetic diagnostics and the next WHO classification
Speaker: C. Reifenberger (Germany)
New devices and strategies for brain tumour surgery
Speaker: C. Watts (United Kingdom)
Discussion & Roundup

Tuesday 28 September 2015

Special Session: Advances in the Management of Low Grade Gliomas
---
21:30 - 22:30
Chair: C. Watts (United Kingdom)
The importance of extent of resection
Speaker: S. Torn (Germany)
Does an optimal chemotherapy treatment exist in adults?
Speaker: R. Soffetti (Italy)
Radiotherapy techniques and indications for the treatment of low grade gliomas
Speaker: S. Corbo (Germany)
Discussion

Immunology in Brain Tumours
Scientific Symposium: Onco-immunology in Brain Tumours
---
17:00 - 19:30
Chair: R. Soffetti (Switzerland)
Co-Chair: A. Erciu (Romania)
The immune microenvironment in gliomas: Scientific concepts
Speaker: M. Pfistner (Germany)
Immunotherapy biomarkers in extracranial tumours and their potential role in brain tumours
Speaker: M. Preusser (Austria)
Immunotherapy-response assessment in extracranial tumours and potential issues in brain tumours
Speaker: D. Bנית (Israel)
Immunotherapy - current trials
Speaker: M. Walter (Switzerland)
Discussion & Roundup

Monday 28 September 2015

Teaching Lecture: Antiangiogenic Therapies in Neuro-Oncology: Current State of Development
---
08:00 - 08:45
Chair: R. Soffetti (Italy)
Speaker: W. Wulk (Germany)
Integrated Session: Novel Approaches to Brain Metastases
---
09:15 - 11:15
Chair: S. Combs (Germany)
Co-Chair: A. Erciu (Romania)
Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Papad (United Kingdom)
Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Preusser (Austria)
Novel systemic therapy approaches to brain metastases: Melanoma
Speaker: D. Schadendorf (Germany)
Advances in loco-regional treatments
Speaker: M. Borsky (United Kingdom)
Tolerability of brain metastasis treatments
Speaker: R. Soffetti (Italy)
Response assessment in brain metastases
Speaker: H. Lin (USA)
Discussion & Roundup

Discussion & Roundup

Wednesday 29 September 2015

Special Session: How to Pay for New “Innovative” Anti-cancer Drugs?
---
11:30 - 12:30
Chair: A. Astier (France)
A new way to pay high costly drugs: Payment for the performance
Speaker: J. M. Gagner (France)
Does the claims of “innovation” of new anticancer drugs justify their too high costs?
Speaker: G. Wiedemann (Germany)
Cost constraints in cancer treatment: What can nations do?
Speaker: J. M. Gagner (France)
Discussion
TDM in pediatric oncology

Speaker: C. Csajka (Switzerland)

Targeted therapies? Is it useful to follow drug levels for TDM of cytotoxic drugs

Speaker: G. Veal (United Kingdom)

State of the art of HIPEC clinical pharmacokinetic aspects of HIPEC

Speaker: I. Netikova (Czech Republic)

Intraperitoneal Chemotherapy

Pharmacy Aspects of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Chair: C. Csajka (Switzerland)

17:00 - 18:30

Special Session: Oncology Pharmacy Aspects of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

14:30 - 14:50

Safe handling considerations in HIPEC (Phase I-II trials)

Speaker: A. Petruzelka (Czech Republic)

14:50 - 15:10

Pharmacokinetic aspects of HIPEC

Speaker: I. Netikova (Czech Republic)

15:10 - 15:30

State of the art of HIPEC clinical benefits

Speaker: A. Petruzelka (Czech Republic)

15:30 - 15:50

Discussion

Scientific Symposium: Therapeutic Drug Monitoring in Cancer

09:00 - 10:30

Monday 28 September 2015

Special Session: The Quality of Reporting Clinical Trials

12:30 - 12:50

Chair: C. Ditsch (Austria)

Why the reported results of clinical trials are often false

Speaker: To be announced

12:50 - 13:10

Under-reporting of harm in clinical trials

Speaker: B. Seruga (Slovenia)

Use and misuse of efficacy endpoints in phase III trials

Speaker: J. Drouard (France)

Discussion

Special Session: Evaluating Clinical Benefit of Cancer Drugs across Tumours

13:10 - 13:30

Chair: G.E. De Brijs (Netherlands)

Clinical benefit scale: The European perspective

Speaker: M. Piccart (Belgium)

Clinical benefit scale: The challenge of fairness

Speaker: G. Dafni (Greece)

Clinical benefit scale: The EMA opinion

Speaker: F. Pignatti (United Kingdom)

The effect of CBS on patient care: The patient’s perspective

Speaker: J. Oliver (United Kingdom)

Discussion

Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics

09:00 - 10:30

Monday 28 September 2015

Companion diagnostic co-development in personalised medicine (including tumour cell culturing) and in vivo

Speaker: M. Vassil (United Kingdom)

Is MRD a valid surrogate endpoint for evaluation of new drugs in leukaemia? Speaker: M. Voloshin (Italy)

Discussion & Roundup

Tuesday 29 September 2015

Scientific Symposium: Bayesian, Adaptive and Rare Disease Designs

09:00 - 10:30

Chair: U. Dafni (Greece)

Co-Chair: B. Ryd (Sweden)

Design in rare disease: The oncologist perspective

Speaker: P. Cusi (Italy)

Implementing innovative trial design in small patient populations in childhood cancers

Speaker: K. Rhee (United Kingdom)

Pitfalls and advantages of using adaptive trial designs in phase III trials

Speaker: M. Mauzer (Belgium)

Multi-arm, multi-stage designs: Are they deliverable?

Speaker: M. Sydes (United Kingdom)

Myelodysplastic syndrome: The epigenetic model for drug development?

Speaker: G. Garcia-Manero (USA)

Discussion & Roundup

Special Session: The Global Impact of the EU Paediatric Regulation across All Ages

11:35 - 12:15

Chair: P. Krams (United Kingdom)

Implementing the Paediatric Regulation: Lessons learnt from the first 5 years?

Speaker: R. Berrend (United Kingdom)

Unintended consequences of regulatory initiatives in childhood and adult cancer drug development

Speaker: P. Adamson (USA)

The Paediatric Regulation: Force for good or evil for cancer drug development?

Speaker: G. Vassil (France)

Discussion

Special Session: Reducing the Size of the Drug Development Graveyard

12:30 - 13:00

Chair: C. Vens (Netherlands)

Considering resistance mechanisms and genetic tumour context

Speaker: R. Bernards (Netherlands)

Drug development approaches and inconsistencies in pharmacogenomics studies

Speaker: J. Quackenbush (USA)

Good drugs, bad trials

Speaker: R. Plummer (United Kingdom)

Discussion

Early Drug Development

Sunday 27 September 2015

Teaching Lecture: Use of the Preparative Window for Early Drug Development

08:00 - 08:45

Chair: R. Plummer (United Kingdom)

Scientific Symposium: New Drugs on the Horizon I

09:15 - 10:45

Chair: J.M. Schellens (Netherlands)

Co-Chair: W. Eberhardt (Germany)

Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What’s next?

Speaker: E. Blank (Netherlands)

Lung cancer: New targets, new drugs, will we eventually even improve survival?

Speaker: M. O’Brien (United Kingdom)

Myelodysplastic syndrome: The epigenetic model for drug development?

Speaker: G. Garcia-Manero (USA)

Multiple myeloma: Of new drugs and new combinations

Speaker: P. Moreau (France)

Discussion & Roundup

Debate: This House Believes that Single Agent Activity is Required for Development in Combination Therapy

15:15 - 16:15

Moderator: R. Salavou (Spain)

Speaker in favour: J.H.M. Schellens (Netherlands)

Speaker against: J. M. Schellens (Netherlands)

Seconder against: A. Chalmers (United Kingdom)

Seconder in favour: M. van Kranen (Netherlands)

Discussion & Voting

Monday 28 September 2015

Scientific Symposium: New Drugs on the Horizon II

09:15 - 10:45

Chair: E. Raymond (Switzerland)

Co-Chair: M. Schadlen (Germany)

TNBC: Biomarkers and opportunities for individualised therapy

Speaker: F. Cardoso (Portugal)

Prostate cancer: From therapeutic nihilism to diversity in treatment options - what can be added?

Speaker: A. Blank (Belgium)

Multiple myeloma: Of new drugs and new combinations

Speaker: P. Moreau (France)

Discussion & Roundup

Gastrointestinal Malignancies - Colorectal Cancer

Saturday 26 September 2015

Teaching Lecture: What We Know and What We Don’t Know (Yet!) about Targeted Agents in Colorectal Cancer

07:45 - 08:30

Chair: C.A. Kurt (Netherlands)

Co-Chair: G. Torrisi (Italy)

Scientific Symposium: New Insights in Colon Cancer

16:45 - 18:15

Chair: D. Aul (Germany)

Co-Chair: P. Laurent-Puig (France)

Biomarkers to guide therapy today, what to assess and how

Speaker: H. Van Kroonen (Netherlands)

Novel insights into CRC biology

Speaker: S. Tegar (Belgium)

The immune landscape of colon cancer

Speaker: J. Galon (France)

Novel insights on tumour adaptation and clinical implications

Speaker: E.S. Kopetz (USA)

Discussion & Roundup

Sunday 27 September 2015

Debate: This House Believes that Supplementary Rectal Irradiation Can Avoid Surgery and Achieve more Complete Clinical Remission

11:30 - 12:30

Moderator: R. Rutten (Netherlands)

Speaker in favour: C. Nauta (Netherlands)

Speaker against: D. Selby (Metsopfo (United Kingdom)

Second against: A. Chalmers (United Kingdom)

Second in favour: M. van Kranen (Netherlands)

Discussion & Voting

Sunday 27 September 2015

Teaching Lecture: Use of the Preparative Window for Early Drug Development

08:00 - 08:45

Chair: R. Plummer (United Kingdom)

Scientific Symposium: New Drugs on the Horizon I

09:15 - 10:45

Chair: J.M. Schellens (Netherlands)

Co-Chair: W. Eberhardt (Germany)

Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What’s next?

Speaker: E. Blank (Netherlands)

Lung cancer: New targets, new drugs, will we eventually even improve survival?

Speaker: M. O’Brien (United Kingdom)

Myelodysplastic syndrome: The epigenetic model for drug development?

Speaker: G. Garcia-Manero (USA)

Multiple myeloma: Of new drugs and new combinations

Speaker: P. Moreau (France)

Discussion & Roundup

Debate: This House Believes that Single Agent Activity is Required for Development in Combination Therapy

15:15 - 16:15

Moderator: R. Salavou (Spain)

Speaker in favour: J.H.M. Schellens (Netherlands)

Speaker against: J. M. Schellens (Netherlands)

Seconder against: A. Chalmers (United Kingdom)

Seconder in favour: M. van Kranen (Netherlands)

Discussion & Voting

Monday 28 September 2015

Scientific Symposium: New Drugs on the Horizon II

09:15 - 10:45

Chair: E. Raymond (Switzerland)

Co-Chair: M. Schadlen (Germany)

TNBC: Biomarkers and opportunities for individualised therapy

Speaker: F. Cardoso (Portugal)

Prostate cancer: From therapeutic nihilism to diversity in treatment options - what can be added?

Speaker: A. Blank (Belgium)

Multiple myeloma: Of new drugs and new combinations

Speaker: P. Moreau (France)

Discussion & Roundup

Gastrointestinal Malignancies - Colorectal Cancer

Saturday 26 September 2015

Teaching Lecture: What We Know and What We Don’t Know (Yet!) about Targeted Agents in Colorectal Cancer

07:45 - 08:30

Chair: C.A. Kurt (Netherlands)

Co-Chair: G. Torrisi (Italy)

Scientific Symposium: New Insights in Colon Cancer

16:45 - 18:15

Chair: D. Aul (Germany)

Co-Chair: P. Laurent-Puig (France)

Biomarkers to guide therapy today, what to assess and how

Speaker: H. Van Kroonen (Netherlands)

Novel insights into CRC biology

Speaker: S. Tegar (Belgium)

The immune landscape of colon cancer

Speaker: J. Galon (France)

Novel insights on tumour adaptation and clinical implications

Speaker: E.S. Kopetz (USA)

Discussion & Roundup

Sunday 27 September 2015

Debate: This House Believes that Supplementary Rectal Irradiation Can Avoid Surgery and Achieve more Complete Clinical Remission

11:30 - 12:30

Moderator: R. Rutten (Netherlands)

Speaker in favour: C. Nauta (Netherlands)

Speaker against: D. Selby (Metsopfo (United Kingdom)

Second against: A. Chalmers (United Kingdom)

Second in favour: M. van Kranen (Netherlands)
Detection of predictive biomarkers in prostate cancer with novel molecular tools
Speaker: T. Van Der Kwast (Canada)

Panel: V. Khoo (United Kingdom)
Radiotherapist
Panel: V. Khoo (United Kingdom)

Panel: T. van der Kwast (Canada)

Predictive factors for treatment choice in metastatic castration resistant prostate cancer
Speaker: H. Schir (USA)

Discussion & Roundup

Sunday 27 September 2015

Debate: This House Believes that Androgen Deprivation Therapy is Indicated in Combination with Adjuvant or Salvage Radiotherapy for Localised/Relapsed Prostate Cancer

Panel Discussion: Advanced disease
Panel: T. de Reijke (Netherlands)

Panel: V. Khoo (United Kingdom)

Radiotherapist
Panel: V. Khoo (United Kingdom)

Radiologist
Panel: J. Boens (Netherlands)

Pathologist
Panel: T. Van Der Kwast (Canada)

Monday 28 September 2015

Special Session: High Risk and Locally Advanced Prostate Cancer

11:30 - 12:30

Chair: M. Piret (Belgium)

Place of radiotherapy
Speaker: A. Boss (France)

Place of drug therapy
Speaker: V. Gaggin (Finland)

Place of surgery
Speaker: A. Weidner (Germany)

Discussion

Tuesday 29 September 2015

Society Session: European Association of Urology (EAU) - Urothelial Cancer in 2015

09:00 - 11:00

Chair: A. Stenzl (Germany)

Risk stratification of urothelial cancer in the lower and upper urinary tract
Speaker: S. Shariat (Austria)

How to prevent progression of early stage urothelial cancer
Speaker: C. Gabrilove (USA)

Matula Award Lecture: Biomarkers in urothelial cancer: When and where to use
Speaker: M. Roupret (France)

Does minimisation of surgery improve the outcome of cystectomy for urothelial cancer?
Speaker: P. Witkamp (Sweden)

Treatment of Urothelial Cancer in the octogenarians
Speaker: M. Clarke (United Kingdom)

Scientific Symposium: Biology Based Selected Drugs in Ovarian Cancer Treatment

17:00 - 18:30

Chair: R. Guazzoni (Italy)
Co-Chair: B. Vergote (Belgium)

Drug acting on ovarian cancer cells and tumour microenvironment
Speaker: M. Driessens (Italy)

Folate receptor blockers
Speaker: J. Barentsz (Netherlands)

Treatment opportunities for homologous recombinant deficiency (PKD) inhibitors
Speaker: S. Bener (United Kingdom)

Immunotherapy opportunities in ovarian cancer
Speaker: C. Divin (Switzerland)

Discussion & Roundup

Tuesday 29 September 2015

Teaching Lecture: Laparoscopic and Robotic Surgery in the Treatment of Gynaecological Malignancy

08:00 - 08:45

Chair: G. Ferrari (Italy)
Speaker: C. Scambia (Italy)

Debate: This House Believes that Ovarian Platinum-Sensitive Carcinoma in Relapse Needs Platinum Based Chemotherapy

12:15 - 12:45

Moderator: J. Ray-Coquard (France)
Speaker in favour: J. Ledermann (United Kingdom)
Speaker against: N. Ciliberto (Italy)
Second against: A. González Martín (Spain)

Discussion & Voting

Monday 28 September 2015

Teaching Lecture: Image Guided Dose and Volume Adaptation in Cervix Cancer

08:00 - 08:45

Chair: P. Teahan (United Kingdom)
Speaker: R. Pötter (Belgium)

Special Session: New Trends in Cervical Cancer Chemotherapy and Radiation Oncology

11:30 - 12:30

Chair: A. Pujols (Spain)

Novel Systemic treatments and immunotherapy - how to combine
Speaker: R. Vis (Italy)

IMRT: Stargate to more intense chemotherapy schedules
Speaker: A. Hopp (USA)

Late toxicity and quality of life results
Speaker: P. Teahan (United Kingdom)

Discussion

Scientific Symposium: Novel Look to Chronic Lymphoid Leukaemia

09:00 - 11:15

Chair: M. Ladetto (Italy)
Co-Chair: S.A. Pileri (Italy)

The molecular basis of CLL
Speaker: N. Schmitz (Germany)

The CLL microenvironment
Speaker: M. Ghielmini (Switzerland)

The CLL microenvironment
Speaker: J. Radford (United Kingdom)

Discussion & Roundup

Monday 28 September 2015

Teaching Lecture: How to Stage and Treat Hodgkin Lymphoma in the Era of PET

08:00 - 08:45

Chair: M. Oehler (Switzerland)
Speaker: J. Bedford (United Kingdom)


09:15 - 10:45

Chair: N. Schmitz (Germany)
Co-Chair: S.A. Pileri (Italy)

Biology of T-cell lymphoma
Speaker: P. Gaulard (France)

Frontline treatment
Speaker: F.A. D’Amore (Denmark)

Relapsed disease
Speaker: T.R. Robak (Poland)

Transplantation in T-cell lymphoma
Speaker: P. Corradini (Italy)

Discussion & Roundup

Monday 28 September 2015

Teaching Lecture: How to Stage and Treat Hodgkin Lymphoma in the Era of PET

08:00 - 08:45

Chair: M. Oehler (Switzerland)
Speaker: J. Bedford (United Kingdom)


09:15 - 10:45

Chair: N. Schmitz (Germany)
Co-Chair: S.A. Pileri (Italy)

Biology of T-cell lymphoma
Speaker: P. Gaulard (France)

Frontline treatment
Speaker: F.A. D’Amore (Denmark)

Relapsed disease
Speaker: T.R. Robak (Poland)

Transplantation in T-cell lymphoma
Speaker: P. Corradini (Italy)

Discussion & Roundup

Monday 28 September 2015

Teaching Lecture: How to Stage and Treat Hodgkin Lymphoma in the Era of PET

08:00 - 08:45

Chair: M. Oehler (Switzerland)
Speaker: J. Bedford (United Kingdom)


09:15 - 10:45

Chair: N. Schmitz (Germany)
Co-Chair: S.A. Pileri (Italy)

Biology of T-cell lymphoma
Speaker: P. Gaulard (France)

Frontline treatment
Speaker: F.A. D’Amore (Denmark)

Relapsed disease
Speaker: T.R. Robak (Poland)

Transplantation in T-cell lymphoma
Speaker: P. Corradini (Italy)

Discussion & Roundup
Special Session: Genetic Traits for Myeloid Malignancies
- 21:30 - 22:30
Chair: J. Stary (Czech Republic)
Current concepts for familial AML
Speaker: J. Pflugshaupt (United Kingdom)
GATA deficiency
Speaker: M. Wlodarski (Germany)
Genetic counselling
Speaker: B. Schlegelberger (Germany)

Discussion
Tuesday 29 September 2015
Teaching Lecture: The Spectrum of Cutaneous Lymphomas: From Molecular Biology to Therapy
- 08:00 - 08:45
Chair: M. Federspil (Italy)
Speaker: R. Bommer (Switzerland)
Debate: This House Believes that We Should Treat First Line Advanced Follicular Lymphoma without Chemotherapy
- 11:15 - 12:15
Moderator: A. List (United Kingdom)
Speaker: M. Shelerins (Switzerland)
Speaker against: M. Federspil (Italy)
Seconder in favour: G. Sallese (France)
Speaker against: M. Pfeilmann (Germany)

Discussion & Voting
HEAD AND NECK CANCER
Saturday 26 September 2015
Teaching Lecture: Dose Escalation or De-Escalation in Head and Neck Cancer?
- 07:45 - 08:30
Chair: D. Zips (Germany)
Speaker: V. Gregoire (Belgium)
Debate: This House Believes that Concurrent Chemotherapy Combined with Hyperfractionated Radiotherapy Should Be the Current Standard in HPV Negative Locally Advanced Head and Neck Cancer
- 12:15 - 13:15
Moderator: A. Pyrin (Greece)
Speaker in favour: P. Blanchard (France)
Speaker against: J.C. Efron (Denmark)
Seconder in favour: W. Budach (Germany)
Seconder against: M. Merkato (Italy)

Discussion
IMAGING
Saturday 26 September 2015
Special Session: Minimally Elevated PSA after Prostatectomy: Hold Your Horses or All Hands on Deck?
- 13:15 - 16:15
Chair: W. C. Oyen (Netherlands)
Role of advanced MRI for detection of minimal disease
Speaker: H.C. Thiery (Switzerland)
Role of PSMA-PEt-CT for detection of minimal disease
Speaker: B.J. Knoss (Australia)
All hands on deck: Early image-guided high-precision treatment
Speaker: V. Athos (United Kingdom)
Hold your horses: Wait and see, do not over treat
Speaker: P. Abrahamsson (Sweden)

Discussion
SUNDAY 27 SEPTEMBER 2015
Multidisciplinary Tumour Board: Breast Cancer
- 11:30 - 12:30
Chair: P. Peeters (Netherlands)
Case presentation by young oncologist: Early disease
Speaker: I. Krudt (Belgium)
Case presentation by young oncologist: Locally advanced disease
Speaker: V. Vinceti (Italy)

Panel Discussion: Locally advanced disease

Case presentation by young oncologist: Advanced disease
Speaker: M. Ferss (Italy)

Panel Discussion: Advanced disease
Pathologist
Panel: H.C. Russnes (Norway)
Medical Oncologist
Panel: F. Cardoso (Portugal)
Surgical Oncologist
Panel: A. Benitez (Spain)
Pathologist
Panel: M. Kivisik (United Kingdom)
Medical Oncologist
Panel: M. Campone (France)
Oncology Nurse
Panel: P. Vannekom (Switzerland)

Multidisciplinary Tumour Board: Gynaecological Tumours – Prostate Cancer
- 12:30 - 13:30
Chair: B. Escudier (France)
Case presentation by young oncologist: Early disease
Speaker: G. Giannarini (Switzerland)
Case presentation by young oncologist: Locally advanced disease
Speaker: B. De Bari (Switzerland)

Panel Discussion: Locally advanced disease

Case presentation by young oncologist: Advanced disease
Speaker: M.A. Ozturk (Turkey)

Panel Discussion: Advanced disease
Urologist
Panel: P. Von der Voert (Switzerland)
Radiologist
Panel: J. Barentsz (Netherlands)
Pathologist
Panel: T. Van Der Kruis (Canada)

MONDAY 28 SEPTEMBER 2015
Teaching Lecture: Image-Guided Dose and Volume Adaptation in Cervix Cancer
- 08:00 - 08:45
Chair: P. Hoskin (United Kingdom)
Speaker: R. Pötter (Australia)
Debate: This House Believes that Mammographic Screening Should Be Discontinued
- 11:30 - 12:30
Moderator: M. Belli (Italy)
Speaker in favour: P. Zaffaroni (Italy)
Speaker against: G. Lugari (Netherlands)
Seconder in favour: G. Liefers (Netherlands)
Seconder against: B. Borisch (Switzerland)

Discussion & Voting
Multidisciplinary Tumour Board: Gastrointestinal Malignancies – Colorectal Cancer
- 11:30 - 12:30
Chair: G. Beets (Netherlands)
Case presentation by young oncologist: Early disease
Speaker: J. Van der Vorst (Netherlands)
Case presentation by young oncologist: Locally advanced disease
Speaker: D. Colvin (Italy)

Panel Discussion: Locally advanced disease
IMMUNOTHERAPY OF CANCER

Saturday 26 September 2015

Scientific Symposium: Cellular Immunotherapy of Cancer

10:30 - 12:00

Chair: R. Glynne-Jones (United Kingdom)

Introduction
Speaker: A. Melcher (United Kingdom)

Making the most of dendritic cell-based immunotherapy
Speaker: C. Figdor (Netherlands)

Is cancer immunosurveillance relevant?
Speaker: C. June (USA)

Discussion & Roundup

Tuesday 29 September 2015

Teaching Lecture: Staging the Ailills: Imaging and Sentinel Node Technologies

08:00 - 08:45

Chair: L. Wyld (United Kingdom)

Introduction
Speaker: T. Helleday (Sweden)

Molecular basis for radiotherapy in synergy with immunotherapy
Speaker: S. Demars (USA)

Radiotherapy, immunotherapy and virotherapy riddles
Speaker: K. Harrington (United Kingdom)

Learning radioimmunotherapy
Speaker: P. Dehdashti (Germany)

Discussion

Tuesday 29 September 2015

Integrated Session: ImmunoTherapy in NSCLC - 2015

09:00 - 11:00

Chair: L. Paz-Ares (Spain)

Introduction
Speaker: L. Paz-Ares (Spain)

Lung cancer: An immunogenic tumour?
Speaker: S.A. Bultitude (United Kingdom)

Any place for vaccination strategies?
Speaker: J. Valentin (Italy)

Check point inhibitors - where do we stand and where are we going?
Speaker: M. Stein (Germany)

Biomarkers - a realistic perspective?
Speaker: K. Kerr (United Kingdom)

Discussion & Roundup

Sunday 27 September 2015

Educational Symposium: Advances in Cancer Therapy Through Modulation of the Immune System

09:15 - 11:15

Chair: B. Van den Eynde (Belgium)

Role of the immune system on the outcome of cancer therapy
Speaker: C. Coukos (Switzerland)

How does imaging radiation contribute to the induction of anti-tumour immunity?
Speaker: G. Althoff (Germany)

Targeting tumour microenvironment
Speaker: P. Albañas (Italy)

Adoptive cell therapy
Speaker: A. Hsiaw (United Kingdom)

Discussion & Roundup

Sunday 27 September 2015

Integrated Session: Immunotherapy in the Management of Metastatic Melanoma

09:00 - 11:00

Chair: A.M.M. Eggermont (France)

Introduction
Speaker: A.M.M. Eggermont (France)

Biomarkers for the complex biology of melanoma immunotherapy
Speaker: C. Robert (France)

Immunogens and immunostimulatory monoclonal antibodies
Speaker: I. Meiro (Spain)

Melanoma targeted therapies in the interface with immunotherapy
Speaker: A. Ribas (USA)

Virotherapy and immunotherapy
Speaker: A. Melcher (United Kingdom)

Discussion & Roundup

Sunday 27 September 2015

Teaching Lecture: Technical Innovations in Radiotherapy

08:00 - 08:45

Chair: V. Valentini (Italy)

Biomarkers - a realistic perspective?
Speaker: C. Brown (United Kingdom)

By imaging
Speaker: A. Ribas (Italy)

By drug combination
Speaker: C. Koehne (Germany)

Introduction
Speaker: A.F. Sobrero (Italy)

Is cancer immunosurveillance relevant?
Speaker: C. June (USA)

Discussion & Roundup

Sunday 27 September 2015

Special Session: Think Big: Larga Databases for Research in Radiation Oncology

15:45 - 16:45

Chair: M. Baumann (Germany)

Big databases and outcome research: Opportunities and challenges for radiation oncology
Speaker: L. van Eijker (Netherlands)

Radiation Ris: Databases for individualised radiation oncology
Speaker: M. Krause (Germany)

The breast cancer example: Lesson from large databases
Speaker: L. Mortensen (Denmark)

Discussion

Sunday 27 September 2015

Scientific Symposium: New Trends in Molecular Targeting for Radiation Oncology

16:45 - 18:15

Chair: Y. Shih (Israel)

Immunotherapy and radiation therapy
Speaker: E. Deutsch (France)

The link between receptors and signalling pathways and radiation therapy
Speaker: K. Harrington (United Kingdom)

Angiogenesis and tumour vascularisation influences radiation effects
Speaker: M. Pruschy (Switzerland)

Why DNA repair is so important for radiation oncologists
Speaker: T. Helleday (Sweden)

Discussion
**Educational Symposium: Radiation Combined with Targeted Agents- The Example of Head and Neck Cancer**
- **16:45 - 18:45**
  - Chair: M. Krause (Germany)
  - Principles and theory behind: Speaker: M. Krause (Germany)
  - The clinical outcome: Speaker: L. Lloreta (Italy)
  - How to manage toxicity: Speaker: E. Deutsh (France)
  - The HPV story: Speaker: J. Erikson (Denmark)

**Debate: This House Believes that Local Radiation Therapy Also Has Therapeutic Effects Outside the Radiation Fields and thereby Contributes to Treatment Outcome**
- **11:30 - 12:30**
  - Moderator: M. Verheij (Netherlands)
  - Speaker in favour: F. Wenz (Germany)
  - Speaker against: B. Offenbacher (Germany)
  - Second speaker in favour: S. Peters (Switzerland)
  - Second speaker against: D. Verdermark (Sweden)
  - Discussion & Voting

---

**LUNG CANCER - LOCALISED/LOCAL REGIONAL AND METASTATIC**

**Saturday 26 September 2015**

**Teaching Lecture: Personalised Radiotherapy: Dream or Reality?**
- **08:00 - 08:45**
  - Chair: P. Poortmans (Belgium)
  - Speaker: M. Baumann (Germany)
  - Scientific Symposium: High-Tech Innovations for Precision Radiation Oncology: Concept, Status and Clinical Benefit
  - **09:00 - 10:30**
    - Chair: P. Poortmans (Belgium)
    - Speaker: C. Faivre-Finn (United Kingdom)
    - How can protons contribute to radiation oncology: Speaker: M. Schwarz (Italy)

**Lung Cancer Screening and Prevention**
- **15:15 - 16:15**
  - Chair: R. van de Velzen (Belgium)
  - MR-Linac is a way to improve treatment delivery: Speaker: M. van Dijk (Netherlands)
  - Discussion & Roundup

**Society Session: European Society for Radiotherapy & Oncology (ESTRO)**
- **09:15 - 11:15**
  - Chair: P. Poortmans (Belgium)
  - Regaud Award Lecture: Minimal effective treatments in the personalised era: The breast model: Award Lecture: R. Grech (Italy)
  - ESTRO Honorary Members Award Lectures
  - Title to be announced: Award Lecture: A. Lietman (USA)
  - Title to be announced: Award Lecture: A. Casseres (Spain)
  - Company Award Lectures
  - Accuracy Award: Award Lecture: To be announced
  - Varian Award: Award Lecture: To be announced

**Sunday 27 September 2015**

**Multidisciplinary Tumour Board: Lung Cancer**
- **11:30 - 12:30**
  - Chair: J. Vansteenkiste (Belgium)
  - Lung cancer prevention and smoking cessation: Speaker: F. Collini (Italy)
  - Lung cancer screening: Ready for standard of care in Europe: Speaker: G. Veronesi (Italy)
  - Discussion

**Special Session: Lung Cancer - Collection of Rare Cancers**
- **16:45 - 18:45**
  - Chair: R. Vescovi (France)
  - Targets in squamous cell carcinoma: Speaker: B. Besse (France)
  - Targets in adenocarcinoma: Speaker: J. C. Soria (France)
  - Targets in SCLC: Speaker: M. van Vulpen (Netherlands)
  - Discussion

**Scientific Symposium: Innovations Broadening the Horizon for Locally-Advanced Non-Small Cell Lung Cancer**
- **17:00 - 18:30**
  - Chair: Y. C. Leans (Belgium)
  - Co-Chair: B. Besse (France)
  - New insights in tumour biology: Speaker: L. Blumstein (Switzerland)
  - Minimally invasive surgery for locally advanced tumours: Speaker: M. Styblo (USA)
  - Novel radiotherapy technology improving the therapeutic index: Speaker: J. A. Boland (Netherlands)
  - Discussion & Roundup

**Discussion & Roundup**
- **11:30 - 12:30**
  - Moderator: C. Veronesi (Italy)
  - Speaker in favour: Y. Van Netterbeke (Belgium)
  - Speaker against: S. Novello (Italy)
  - Moderator: G. Veronesi (Italy)
  - Speaker: B. Besse (France)
  - Discussion & Roundup
Scientific Symposium: Evolution of Targeted Therapies in Lung Cancer: Where Are We Today and Where Are We Going?

Special Session: Resistance in Patients with Oncogenic Alterations

22:15 - 22:15
Chair: D.R. Camidge (USA)
Tumour cells heterogeneities evolution
Speaker: C. Swanton (United Kingdom)
Overcoming resistance in patients with ALK translocations
Speaker: D.K. Camidge (USA)
Perspectives in management of EGFR resistance
Speaker: F. Capussotti (Italy)
Discussion

MELANOMA AND SKIN CANCER

Monday 28 September 2015

Teaching Lecture: Immunotherapy in Melanoma: From Frustration to Enthusiasm

08:00 - 08:45
Chair: P.A. Ascierto (Italy)
Speaker: J. Feng (China)
Integrated Session: Novel Approaches to Brain Metastases

09:45 - 11:15
Chair: S. Combs (Germany)
Co-Chair: A. Ursin (Romania)
Biography of brain metastases
Speaker: P.S. Steeg (USA)
Novel systemic therapy approaches to brain metastases: Lung
Speaker: S. Popat (United Kingdom)
Novel systemic therapy approaches to brain metastases: Breast
Speaker: M. Puschett (France)
Novel systemic therapy approaches to brain metastases: Melanoma
Speaker: D. Schadendorf (Germany)
Advances in loco-regional treatments
Speaker: M. Batsal (United Kingdom)
Tolerability of brain metastasis treatments
Speaker: A. Testori (Italy)
Response assessment in brain metastases
Speaker: N. Lin (USA)
Discussion & Roundup

ONCOLOGY NURSING

Saturday 26 September 2015

Teaching Lecture: Online Information and Support: Benefits and Risks

07:45 - 08:30
Chair: A. Magouleas (Switzerland)
The role of patient experiences as an online resource
Speaker: L. Carrasquero (United Kingdom)
Benefits and risks of e-health information sources for people living with cancer
Speaker: V. Vodnich-de Leau (Netherlands)
Discussion & Roundup

Special Session: How Do We Sequence or Combine Immunotherapies with Targeted Therapies in Melanoma?

11:15 - 12:15
Chair: P.A. Ascierto (Italy)
The US view
Speaker: A. Ribas (USA)
The Australian view
Speaker: G. Long (Australia)
The European view
Speaker: R. Robert (France)
Discussion

Tuesday 29 September 2015

Teaching Lecture: Update on the Role of Surgery in Melanoma: From Margins to SLNB to Metastasectomy

08:00 - 08:45
Chair: A.M.M. Eggermont (France)
Speaker: A. Testori (Italy)
Integrated Session: Immunotherapy in the Management of Metastatic Melanoma

09:00 - 11:00
Chair: A.M.M. Eggermont (France)
Co-Chair: PA. Ascierto (Italy)
Introduction
Speaker: A.M.M. Eggermont (France)
Biomarkers for the complex biology of melanoma immunotherapy
Speaker: C. Robert (France)
Immunogens and immunostimulatory monoclonal antibodies
Speaker: J. Matson (Spain)
Melanoma targeted therapies in the interface with immunotherapy
Speaker: A. Ribas (USA)
Virotherapy and immunotherapy
Speaker: A. Meeker (United Kingdom)
Discussion & Roundup

Oncology Nursing Society (EONS) Conference

Tuesday 29 September 2015

Teaching Lecture: Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centred Person-Centre
Sunday 27 September 2015

Special Session: Living with and Beyond Cancer

Chair: E. Van Mullem (Netherlands)

The benefits of physical activity during and following cancer treatment: The patient perspective
Speaker: N. House (United Kingdom)

Living with cancer risk: Supporting patients and families with examples from breast cancer
Speaker: D. Roos (Belgium)

Beyond cancer: The fear of cancer recurrence
Speaker: C. Goskrok (United Kingdom)

Discussion

Special Session: Nutrition and Body Image Changes - A Concern for All Patients with Cancer

Chair: M.C. Lacerda (Portugal)

Weight gain during cancer therapy: Issues for cancer practice
Speaker: Y. Weng (Singapore)

Swallowing difficulties: Lessons from head and neck cancer
Speaker: M. Weil (United Kingdom)

Cancer cachexia: What can we do to help?
Speaker: F. Strasser (Switzerland)

Discussion

Scientific Symposium: The Changing Face of Cancer Care for Oncology Nurses: The Rising Demand Being Placed on Cancer Services

Chair: M.C. Lacerda (Portugal)

Co-Chair: K. Laker (Slovenia)

Meeting the support needs of patients, carers & families after cancer treatment
Speaker: C. Foster (United Kingdom)

Factors underpinning workplace stress: Lessons for cancer nursing
Speaker: A. Caruso (Italy)

Multi-disciplinary rehabilitation in advanced bladder cancer
Speaker: B. Theuljen (Denmark)

Reducing emergency cancer admissions: A case study
Speaker: C. Bailey (United Kingdom)

Discussion & Roundup

ONCOLOGY

Saturday 26 September 2015

OncoPolicy Forum: Timebombs in Oncology: Cancer in the Elderly

13:00 - 14:30

Chair: R.A. Audisio (United Kingdom)

With the retirement age increasing in many countries, the number of people working with long-term medical conditions including certain cancers will also increase. Some employers have realised this and are implementing workplace initiatives to address the problem. This session will seek to provide policy solutions for the timebomb of cancer in the elderly.

Monday 28 September 2015

OncoPolicy Forum: EU Funding Opportunities for You and Your Team

11:30 - 12.30

Chair: A. Costa (Italy)

This session will unlock the possibilities for cancer research funding under the EU budget 2014 - 2020. It will enable participants to understand the sometimes complex landscape and identify the most relevant opportunities to benefit from available programmes, such as Horizon 2020.

OncoPolicy Forum: Timebombs in Oncology: The Oncology Workforce

13:00 - 14:30

Chair: To be announced

This session will consist of a multi-disciplinary cancer panel giving their perspectives on the timebomb that is the oncology workforce. Discussion with the audience will seek to solicit possible policy solutions in anticipation of workforce shortages in essential disciplines.

Sunday 27 September 2015

Integrated Session: Tackling Rare Cancers Requiring Specialist Care: European Reference Networks

17:00 - 18:30

Chair: C. Grassi (Italy)

This session will address the cross-border movement of cancer patients and the setting up of European Reference Networks. Patients and the rare cancers community will provide their perspectives on this development.

PAEDIATRIC ONCOLOGY

Saturday 26 September 2015

Teaching Lecture: Myelodysplastic Syndrome - Children & Adults

07:45 - 08:30

Chair: R. Riccardi (Italy)

Co-Chair: C. Nemer (Germany)

Society Session: European Society for Paediatric Oncology (SIOPP)

10:30 - 12.30

Chair: G. Vassal (France)

Details to be announced in the online searchable programme and final programme as updated possible.

Sunday 27 September 2015

Integrated Session: Tackling Lymphoid Malignancies in Children and Adults with the Same Protocols

09:15 - 11:15

Chair: C. Ollier (France)

Co-Chair: C. Heuser (Austria)

Introduction
Speaker: C. Ollier (France)

Moderator: A. von Stackelberg (Germany)

Seconder against: T. Merchant (USA)

Seconder in favour: A. Crellin (United Kingdom)

Speaker against: K. Dieckmann (Austria)

Speaker in favour: B. Timmermann (Germany)

Moderator: K. Pritchard-Jones (United Kingdom)

Debate: This House Believes that Proton and Particle Therapy is Standard Treatment for Paediatric Malignancies

15:15 - 16:15

Moderator: K. Pritchard-Jones (United Kingdom)

Speaker in favour: B. Timmermann (Germany)

Speaker against: K. Dieckmann (Austria)

Seconded in favour: A. Crellin (United Kingdom)

Seconded against: T. Merchant (USA)

Special Session: Precision Medicine and New Drugs for the Treatment of Children and Adolescents with Cancer

17:00 - 18:30

Chair: C. Grassi (Italy)

Tumour molecular profiling to guide new drug development: Experiences from Germany, France, UK and Netherlands
Speaker: S. Pisters (Germany)

Is B-Raf and MEK pathway relevant in paediatric malignancies?
Speaker: A. Geay (France)

Monoclonal antibodies in paediatric acute leukaemias
Speaker: A. von Stackelberg (Germany)

Discussion

Scientific Symposium: Childhood Cancer - Bad Luck or Bad Genes?

16:45 - 18:15

Chair: L. Bugien (France)

Co-Chair: F. Bourdeaut (France)

Status of predisposition to paediatric malignancies: The known and unknown
Speaker: A. Wimmer (Austria)

Dysregulated RAS signalling in paediatric cancer and developmental disorders
Speaker: M. Tartaglia (Italy)

Li-Fraumeni syndrome
Speaker: M. Frebourg (France)

Research and counselling in genetic predisposition to paediatric malignancies: Ethical issues
Speaker: F. Bourdeaut (France)

Discussion & Roundup
Tuesday 29 September 2015

Educational Symposium: Common Approaches & Pathways in Adult and Paediatric Malignancies
15:45 - 16:15
Chair: A. Pearson (United Kingdom)

Lessons and perspective in the treatment of high-risk neuroblastoma: The SIOPEN strategy
Speaker: O. Valumaa-Couzet (France)

Strategies for improving maintenance therapy in high-risk neuroblastoma patients
Speaker: R. Ladebeni (Austria)

Introducing ALK inhibition therapy in neuroblastoma treatment
Speaker: A. Egger (Germany)

Targeting osteosarcoma: What is different between adult and paediatric patients?
Speaker: S. Boland (Germany)

Robust endpoints when evaluating novel “targeted” therapies
Speaker: M. Velocci (Italy)

Discussion & Roundup

Special Session: New Perspective for the Treatment of High-Risk Neuroblastoma
16:45 - 17:45
Chair: A. Pearson (United Kingdom)

Introduction
Speaker: S. Jakobsen (Germany)

Molecular classification of neuroblastoma
Speaker: S. Pfister (France)

Current concepts and future directions in pharmacotherapy of medulloblastoma
Speaker: S. Roobrouck (Germany)

Recent results and current concepts for risk adapted medulloblastoma treatment: Experiences from the German HIT-studies and the SIOPEN-Europe PNET working group
Speaker: S. Roobrouck (Germany)

Optimising efficacy and limiting toxicity of radiotherapy for medulloblastoma
Speaker: S. Combs (Germany)

Management of adult medulloblastoma - using the evidence from children and adolescents
Speaker: A. Brandes (Italy)

What is the definition of an ER+ breast cancer?
Speaker: J. Bergh (Switzerland)

Evaluating and adapting endocrine therapy in HER2++ breast cancer patients?
Speaker: J. Bergh (Switzerland)

Evaluating and adapting endocrine therapy in HER2+++ breast cancer patients?
Speaker: J. Bergh (Switzerland)

Pregnant and adjacent endocrine therapy: Is there any window for opportunity?
Speaker: S. Juch (Germany)

Discussion & Roundup

Scientific Symposium: New Insights in Colorectal Cancer
16:45 - 18:15
Chair: D. Aust (Germany)
Co-Chair: F. Laurent-Puig (France)

Biomarkers to guide therapy today, what to assess and how
Speaker: H. Van Krieken (Netherlands)

Novel insights into CRC biology
Speaker: S. Tapar (Belgium)

The immune landscape of colon cancer
Speaker: J. Cohen (France)

Novel insights on tumour adaptation and clinical implications
Speaker: E.S. Apostolou (USA)

Discussion & Roundup

PATHOLOGY

Saturday 26 September 2015

Teaching Lecture: Use of Liquid Biopsies
07:45 - 08:30
Chair: C. Celik (United Kingdom)
Co-Chair: C. Diuse (United Kingdom)

Evaluating and adapting endocrine therapy in HER2+++ breast cancer patients?
Speaker: J. Bergh (Switzerland)

Evaluating and adapting endocrine therapy in HER2+++ breast cancer patients?
Speaker: J. Bergh (Switzerland)

Pregnant and adjacent endocrine therapy: Is there any window for opportunity?
Speaker: S. Juch (Germany)

Discussion & Roundup

Scientific Symposium: Emerging Developments and Treatment Strategies in HPV Positive Head and Neck Cancer
16:45 - 18:15
Chair: L. Licitra (Italy)
Co-Chair: B. Tombal (Belgium)

Predictive factors for treatment choice in metastatic castration resistant prostate cancer
Speaker: M. Scher (USA)

Discussion & Roundup

Scientific Symposium: The Survivorship of Survivors - The Survivorship of Survivors
08:00 - 08:45
Chair: L.J. Hjorth (Sweden)

10:45 - 11:45
Chair: S.J. Rutkowski (Germany)

13:45 - 14:45
Chair: A. Pearson (United Kingdom)

15:45 - 16:45
Chair: J. Calsetta (Italy)
Co-Chair: A. Bjartell (Sweden)

16:45 - 18:00
Chair: R. Cathomas (Switzerland)
Co-Chair: P. Schmid-Antiqua (Spain)

18:00 - 19:00
Chair: J. Geissler (Germany)
Co-Chair: B. Escher (Switzerland)

19:00 - 19:30
Chair: R.A. Adlina (United Kingdom)
Co-Chair: R. Cluvier (Ireland)

19:30 - 20:00
Chair: T. Friederich (United Kingdom)
Co-Chair: J. Calsetta (Italy)

10:45 - 11:45
Chair: R. Cathomas (Switzerland)
Co-Chair: P. Schmid-Antiqua (Spain)

13:45 - 14:45
Chair: A. Pearson (United Kingdom)
Co-Chair: A. Bjartell (Sweden)

15:45 - 16:45
Chair: J. Calsetta (Italy)
Co-Chair: A. Bjartell (Sweden)
Sunday 27 September 2015

Multidisciplinary Tumour Board: Breast Cancer
- 11:30 - 12:30
Chair: P. Poortmans (Netherlands)
Case presentation by young oncologist: Early disease
Speaker: B. Haas (Netherlands)
Panel Discussion: Early disease
Case presentation by young oncologist: Locally advanced disease
Speaker: A. Hollebecque (France)
Panel Discussion: Locally advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: F. Cellini (Italy)
Panel Discussion: Advanced disease
Pathologist
Panel: H.G. Russnes (Norway)
Medical Oncologist
Panel: F. Cardoso (Portugal)
Surgical Oncologist
Panel: K. Cedermark (Sweden)
Oncology Nurse
Panel: M. Compere (France)

Discussion & Voting

Multidisciplinary Tumour Board: Lung Cancer
- 11:30 - 12:30
Chair: J. Westerhuis (Belgium)
Case presentation by young oncologist: Early disease
Speaker: F. Cellini (Italy)
Panel Discussion: Early disease
Case presentation by young oncologist: Locally advanced disease
Speaker: A. Lagrue (France)
Panel Discussion: Locally advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: A. Calafano (United Kingdom)
Panel Discussion: Advanced disease
Radiation Oncologist
Panel: J.A. Beelers (Netherlands)
Surgical Oncologist
Panel: J. Edwards (United Kingdom)
Pathologist
Panel: E. Brambilla (France)
Radiologist
Panel: J. Cathoel (Belgium)
Oncology Nurse
Panel: K. Cedermark (Sweden)

Special Session: Management of Sarcoma Patients in Reference Centres
- 11:30 - 12:30
Chair: S. Bonvalot (France)
Scandinavian experience
Speaker: M. Eriksson (Sweden)
Treatment in reference centres: The turning point in UK
Speaker: J. Judson (United Kingdom)
Why is it difficult to implement? Next steps
Speaker: B. Haas (Netherlands)
Recent data: Are promises fulfilled?
Speaker: J. Ray-Coquard (France)

Discussion & Voting

Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer
- 15:30 - 16:30
Chair: R. Escudier (France)
Case presentation by young oncologist: Early disease
Speaker: G. Guimaraes (Canada)
Panel Discussion: Early disease
Case presentation by young oncologist: Locally advanced disease
Speaker: A. De Bar (Switzerland)
Panel Discussion: Locally advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: M.A. Gutnry (Turkey)
Panel Discussion: Advanced disease
Urologist
Panel: F. de Ruige (Netherlands)
Radiologist
Panel: W. Lee (United Kingdom)
Radiologist
Panel: B. Bonnem (Netherlands)
Pathologist
Panel: J. van der Kruiz (Canada)

Debate: This House Believes that Molecular Diagnosis of Sarcoma is a Luxury
- 15:30 - 16:15
Moderator: E. de Ruiege (Spain)
Speaker: A. Calafano (United Kingdom)
Speaker: I. Judson (United Kingdom)
Discussion

Scientific Symposium: Muscle Invasive Bladder Cancer
- 17:00 - 18:30
Chair: T. de Ruige (Netherlands)
Co-Chair: C.N. Stornberg (Italy)
Biomarkers in bladder cancer
Speaker: J. Velmi (USA)
Surgical treatments: What is new?
Speaker: L. Schmit (France)
Chemoradiotherapy
Speaker: N.D. James (United Kingdom)
Neo-adjuvant versus adjuvant treatment
Speaker: C.N. Stornberg (Italy)
Panel Discussion: Locally advanced disease
Case Presentation by young oncologist: Locally advanced disease
Speaker: F. Cellini (Italy)
Panel Discussion: Advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: T. de Ruige (Netherlands)

Discussion & Roundup

Scientific Symposium: Gastrointestinal Malignancies - Colorectal Cancer
- 11:30 - 12:30
Chair: G. Berts (Netherlands)
Case presentation by young oncologist: Early disease
Speaker: J. van der Vort (Netherlands)
Biomarkers in bladder cancer
Speaker: J. Velmi (USA)
Surgical treatments: What is new?
Speaker: L. Schmit (France)
Chemoradiotherapy
Speaker: N.D. James (United Kingdom)
Neo-adjuvant versus adjuvant treatment
Speaker: C.N. Stornberg (Italy)
Panel Discussion: Locally advanced disease
Case Presentation by young oncologist: Locally advanced disease
Speaker: F. Cellini (Italy)
Panel Discussion: Advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: T. de Ruige (Netherlands)

Discussion & Roundup

Scientific Symposium: New Drugs on the Horizon II
- 09:45 - 10:45
Chair: E. Raymond (Switzerland)
Co-Chair: M.E. Schuhen (Germany)
TNBC: Biomarkers and opportunities for individualised therapy
Speaker: F. Cardoso (Portugal)
Prostate cancer: From therapeutic nihilism to diversity in treatment options - what can be added?
Speaker: B. Tannen (Belgium)
Multiple myeloma: Of new drugs and new combinations
Speaker: F. Maisonneuve (France)

Discussion & Roundup

Multidisciplinary Tumour Board: Genitourinary Malignancies - Prostate Cancer
- 15:30 - 16:15
Chair: R. Escudier (France)
Case presentation by young oncologist: Early disease
Speaker: G. Guimaraes (Canada)
Panel Discussion: Early disease
Case presentation by young oncologist: Locally advanced disease
Speaker: A. De Bar (Switzerland)
Panel Discussion: Locally advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: M.A. Gutnry (Turkey)
Panel Discussion: Advanced disease
Urologist
Panel: F. de Ruige (Netherlands)
Radiologist
Panel: W. Lee (United Kingdom)
Radiologist
Panel: B. Bonnem (Netherlands)
Pathologist
Panel: J. van der Kruiz (Canada)

Debate: This House Believes that Molecular Diagnosis of Sarcoma is a Luxury
- 15:30 - 16:15
Moderator: E. de Ruiege (Spain)
Speaker: A. Calafano (United Kingdom)
Speaker: I. Judson (United Kingdom)
Discussion

Scientific Symposium: Muscle Invasive Bladder Cancer
- 17:00 - 18:30
Chair: T. de Ruige (Netherlands)
Co-Chair: C.N. Stornberg (Italy)
Biomarkers in bladder cancer
Speaker: J. Velmi (USA)
Surgical treatments: What is new?
Speaker: L. Schmit (France)
Chemoradiotherapy
Speaker: N.D. James (United Kingdom)
Neo-adjuvant versus adjuvant treatment
Speaker: C.N. Stornberg (Italy)
Panel Discussion: Locally advanced disease
Case Presentation by young oncologist: Locally advanced disease
Speaker: F. Cellini (Italy)
Panel Discussion: Advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: T. de Ruige (Netherlands)

Discussion & Roundup

Scientific Symposium: Gastrointestinal Malignancies - Colorectal Cancer
- 11:30 - 12:30
Chair: G. Berts (Netherlands)
Case presentation by young oncologist: Early disease
Speaker: J. van der Vort (Netherlands)
Biomarkers in bladder cancer
Speaker: J. Velmi (USA)
Surgical treatments: What is new?
Speaker: L. Schmit (France)
Chemoradiotherapy
Speaker: N.D. James (United Kingdom)
Neo-adjuvant versus adjuvant treatment
Speaker: C.N. Stornberg (Italy)
Panel Discussion: Locally advanced disease
Case Presentation by young oncologist: Locally advanced disease
Speaker: F. Cellini (Italy)
Panel Discussion: Advanced disease
Case presentation by young oncologist: Advanced disease
Speaker: T. de Ruige (Netherlands)

Discussion & Roundup

Special Session: The Molecular and Histological Classification of Gastro-Oesophageal Cancer: Implications for Treatment
- 11:30 - 12:30
Chair: M. Pidelipo (Spain)
Re-classification of OG Cancer through distinct molecular phenotypes
Speaker: A. Bass (USA)
Implication for therapeutic exploitation
Speaker: D. Cunningham (United Kingdom)
Tailored surgical approach
Speaker: F. Roselli (Italy)

Discussion

Special Session: The Prerequisite for Ideal Biobanking
- 15:30 - 16:15
Chair: J. Dihuer (Switzerland)
How much is important for the basic research the material and the dataset?
Speaker: F. Carreño (Portugal)
From the operating room to the laboratory. The value of surgery standardisation and data collection in a tissue bank
Speaker: G. Corso (Italy)
Interventional radiologist’s perspective
Speaker: F. Perret (Netherlands)

Discussion
ECCO 18 - ESMO 40 - European Cancer Congress - ADVANCE PROGRAMME

Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics

- 17:00 - 18:30
  Chair: S. Livier (Belgium)
  Co-Chair: L.T. Su (Canada)

Pharmacologic biomarkers in the development of stratified cancer medicine
Speaker: Y. Neuh (United Kingdom)
One size doesn't fit all - current status of commonly used surrogate markers across tumours: Paradoxes from colorectal, lung and breast cancer
Speaker: M. Reck (Germany)

Companion diagnostic co-development in personalised medicine (including circulating tumour cells)
Speaker: L. Su (Canada)

Is MRD a valid surrogate endpoint for evaluation of new drugs in leukaemia?
Speaker: M. Vu (Australia)

Discussion & Roundup

Scientific Symposium: How to Select the Best Palliative Treatments on the Basis of Survival and Treatment Outcome

- 17:00 - 18:30
  Chair: Y. Van der Linden (Netherlands)
  Co-Chair: P. Naredi (Sweden)

Prognostic tools in palliative radiotherapy
Speaker: Y. Van der Linden (Netherlands)

Prognostic tools in palliative systemic therapies
Speaker: A. Reyners (Netherlands)

Prognostic tools in palliative surgical care
Speaker: N. Terblanche (United Kingdom)

Nurses’ perspectives on supporting prognostic information in palliative care
Speaker: J. Fokkensfeld (United Kingdom)

Discussion & Roundup

Scientific Symposium: Making Survivor Care Evidence Based for the Growing Number of Survivors: Patients at the Forefront of Their Own Survivorship Care

- 17:00 - 18:30
  Chair: S. Dier (Turkey)
  Co-Chair: J. Tietema (Netherlands)

How late effects in testicular cancer guide follow-up
Speaker: P.J. Nagys (Netherlands)

Exploiting dormant information on long-term follow-up outcome: The EORTC survivorship initiative
Speaker: J. Moser (Portugal)

How to involve the primary care physician in survivor care for growing number of survivors
Speaker: E. Grunfeld (Canada)

Patients in control of navigating their own survivor care plan
Speaker: J. Tietema (Netherlands)

Discussion & Roundup

Integrated Session: Immunotherapy in the Management of Metastatic Melanoma

- 09:00 - 12:00
  Chair: F. Pauwels (Netherlands)

Expanding the range of gene testing as next generation sequencing enters clinical practice
Speaker: F. Pestone (France)

Surgical strategies for gene carriers: Breast conservation versus unilateral or bilateral mastectomy
Speaker: O. Gruen (Italy)

Tailoring chemotherapy for hereditary breast cancer carriers
Speaker: A. Tiot (United Kingdom)

Discussion

Patient Advocacy Session: Ensuring Quality of Treatment

- 16:45 - 18:15
  Chair: S. Dier (Turkey)

What are generics and biosimilars?
Speaker: A. Bergerson (Belgium)

Counterfeits: Generics, substandard drugs, counterfeit medicines - what is the difference?
Speaker: M. Vian (United Kingdom)

Regulating medicines and medical devices
Speaker: To be announced

The European Atlas of Access to Myeloma Treatment
Speaker: E. Liao (United Kingdom)

Discussion

Patient Advocacy Session: Rehabilitation

- 09:00 - 11:00
  Chair: A. Tett (United Kingdom)

Childhood and Adolescents
Speaker: C. Bode (Germany)
Chair: W. van Heren (Belgium)

Family and youth rehabilitation
Speaker: S. Sadler (Germany)

Mentoring: Patients helping each other
Speaker: M. Will (Australia)

Create your future: Supporting survivors into the workforce
Speaker: S. Karam (Australia)

Discussion

Patient Advocacy Session: Cancer Trilogo - What Really Matters to Patients

- 09:15 - 10:45
  Chair: M. Piccart (Belgium)

Triologo: What Really Matters to Patients
Speaker: S. Hovmand Lysdal (Denmark)

What are the priorities for the future?
Speaker: I. Banks (Belgium)

Your Life: For patients who want to take action themselves
Speaker: S. Hovmand Lysdal (Denmark)

Rehabilitation: Summary and analysis of actions among European countries
Speaker: K. Orren (Denmark)

Discussion

Patient Advocacy Session: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics

- 15:00 - 16:15
  Chair: K. Mueless (United Kingdom)
  Chair: B. Park (Spain)

Pain, pride and prejudice
Speaker: K. Mueless (United Kingdom)

The patient and the physician
Speaker: K. Oller (United Kingdom)

The bill of rights
Speaker: P. Taly (United Kingdom)

Discussion

Patient Advocacy Session: Communication - Stop Press Session

- 17:00 - 18:30
  Chair: C. Geissler (Germany)

Wrap up discussion/recommendations from the patient advocacy track
Facilitator: J. Geissler (Germany)

Details to be announced in the online searchable programme and final programme as soon as possible

Monday 28 September 2015

Patient Advocacy Session: Clinical Trials - What Really Matters to Patients

- 09:15 - 10:45
  Chair: M. Pizan (Belgium)
  Co-Chair: B. Wij (Switzerland)
  Panel: AM M. Eegamont (France)
  Panel: J. Wells (United States)
  Panel: L. Su (Canada)

Panel: To be announced

Discussion

PATIENT ADVOCACY

Saturday 26 September 2015

Patient Advocacy Session: Information Provision

- 10:30 - 12:30
  Chair: J. Barri (Belgium)
  Chair: J. Core-Bois (France)

Introduction
Speaker: J. Barri (Belgium)

Biostats for the complex biology of melanoma immunotherapy
Speaker: C. Robert (France)

Immunogens and immunostimulatory monoclonal antibodies
Speaker: M. Molen (Spain)

Melanoma targeted therapies in the interface with immunotherapy
Speaker: A. Rizos (USA)

Virotherapy and immunotherapy
Speaker: A. Aebischer (United Kingdom)

Discussion & Roundup

Special Session: Management Strategies for Hereditary Gene Mutation Carriers with Early Breast Cancer

- 11:30 - 12:30
  Chair: P. Perimets (Netherlands)

What are the priorities for the future?
Speaker: I. Banks (Belgium)

What is genetics?
Speaker: To be announced

Genetic screening: What should you know?
Speaker: J. Brunet (Spain)

Discussion

Patient Advocacy Session: Ensuring Quality of Treatment

- 16:45 - 18:15
  Chair: S. Dier (Turkey)

What are generics and biosimilars?
Speaker: A. Bergerson (Belgium)

Counterfeits: Generics, substandard drugs, counterfeit medicines - what is the difference?
Speaker: M. Vian (United Kingdom)

Regulating medicines and medical devices
Speaker: To be announced

The European Atlas of Access to Myeloma Treatment
Speaker: E. Liao (United Kingdom)

Discussion

Patient Advocacy Session: Rehabilitation

- 09:00 - 11:00
  Chair: A. Tett (United Kingdom)

Childhood and Adolescents
Speaker: C. Bode (Germany)
Chair: W. van Heren (Belgium)

Family and youth rehabilitation
Speaker: S. Sadler (Germany)

Mentoring: Patients helping each other
Speaker: M. Will (Australia)

Create your future: Supporting survivors into the workforce
Speaker: S. Karam (Australia)

Discussion

Patient Advocacy Session: Cancer Trilogo - What Really Matters to Patients

- 09:15 - 10:45
  Chair: M. Pizan (Belgium)
  Co-Chair: B. Wij (Switzerland)
  Panel: AM M. Eegamont (France)
  Panel: J. Wells (United States)
  Panel: L. Su (Canada)

Panel: To be announced

Discussion

Patient Advocacy Session: Communication - Stop Press Session

- 17:00 - 18:30
  Chair: C. Geissler (Germany)

Wrap up discussion/recommendations from the patient advocacy track
Facilitator: J. Geissler (Germany)

Details to be announced in the online searchable programme and final programme as soon as possible

Monday 28 September 2015

Patient Advocacy Session: Clinical Trials - What Really Matters to Patients

- 09:15 - 10:45
  Chair: M. Pizan (Belgium)
  Co-Chair: B. Wij (Switzerland)
  Panel: AM M. Eegamont (France)
  Panel: J. Wells (United States)
  Panel: L. Su (Canada)

Panel: To be announced

Discussion
Sunday 27 September 2015

Teaching Lecture: Long Term Physical Outcomes of Bone Sarcoma Surgery in Children and Young Adults
08:00 - 08:45
Chair: R. Lademann (Austria)
Speaker: R. Grimer (United Kingdom)

Scientific Symposium: Local Treatment is the Key Medical Scientific Question
09:45 - 10:45
Chair: S. Bonvalot (France)
Co-Chair: P. Rutkowski (Poland)
Quality assurance in surgery
Speaker: A. Goyoni (Italy)
Hallmarks of hyperthermia
Speaker: R. Coque (Italy)
New questions for RT in randomised trials
Speaker: A. Rose (Netherlands)

Discussion & Roundup

Supportive Care and Palliation
Saturday 26 September 2015

Scientific Symposium: ECCO/MASCC Joint Symposium
16:45 - 18:15
Details to be announced on the online searchable programme and final programme as soon as possible

Monday 28 September 2015

Teaching Lecture: Developing and Testing Supportive Care Interventions
08:00 - 08:45
Chair: A. Manginas (Switzerland)
Speaker: M. Eichler (Switzerland)

Special Session: The Challenge of Spiritual Caring in Supportive Care and Palliation
13:30 - 16:30
Chair: A. Chruisce (Cyprus)
What does spiritual caring mean - from patient perspective
Speaker: C. Kushlich (USA)
Why is it difficult to care for the patient spiritually?
Speaker: D. Alassis (Malta)

Scientific Symposium: How to Select the Best Palliative Treatments on the Basis of Survival and Treatment Outcome
17:00 - 18:30
Moderator: E. de Alba (Spain)
Speaker in favour: G. Coindre (France)
Speaker against: L. Bokemeyer (Germany)
Second speaker in favour: W. van der Graaf (Netherlands)
Second speaker against: A. La Casse (France)

Discussion & Voting

Special Session: Paediatric Palliative Care - Complexity Calls for Novelty
12:15 - 12:15
Chair: C. Ignacetti (Italy)
Management of cancer related pain
Speaker: To be announced
Home management of dying children
Speaker: To be announced
Psychosocial support for dying children and their parents: The nursing role
Speaker: T. Tzios (Cyprus)

Surgery and Patients Outcomes
Saturday 26 September 2015

Teaching Lecture: Surgery in Synchronous Oligometastatic Disease
07:45 - 08:30
Chair: J.H. Van der Velde (Netherlands)
Speaker: P. Naredi (Sweden)

Society Session: European Society of Surgical Oncology (ESSO)
10:30 - 12:30
Chair: S. Gonzalez-Moreno (Spain)
Presentation of the ESSO Award
Speaker: C. Wijff (United Kingdom)
UEMS approved Surgical Curriculum
Speaker: C. Wijff (United Kingdom)
The training in surgical oncology across the EU
Speaker: J.H. Van der Velde (Netherlands)
Travelling fellowship in surgical oncology across the Atlantic
Speaker: O. Perez (Germany)

The surgical load of MDTs
Speaker: T. Sank (United Kingdom)
Virtual reality, cadaver lab and tele-tutoring: Can new teaching paradigm decrease learning curves assuring surgical quality?
Speaker: O. Pizzi (Italy)

Questions & Answers
Special Session: Highly Skilled Surgery and Patients Outcomes
15:15 - 16:15
Chair: S. Gonzalez-Moreno (Spain)
Learning curve for complex cancer surgery
Speaker: S. Kuusama (Italy)
Locally advanced pelvic lesions
Speaker: P. Tafak (United Kingdom)
Robots: Nurse's role in high-tech surgical theatres
Speaker: O. Lelio (Italy)

Discussion

Scientific Symposium: Neoadjuvant Treatment - When is It of Benefit for the Patient and Doctor?
16:45 - 18:15
Chair: R.A. Audisio (United Kingdom)
Co-Chair: C. Chyane (James United Kingdom)
Surgical issues and cancer outcomes
Speaker: S. Gonzalez-Moreno (Spain)
The timing of radiotherapy in the NT setting
Speaker: J. Bosquet (France)
What does complete response look like?
Speaker: R.G. Beets-Tan (Netherlands)
Pathological CR: Predicament or promise?
Speaker: A. Le Cesne (France)

Discussion & Roundup
Sunday 27 September 2015

Special Session: Excisional Margins in 2015
15:15 - 16:15
Chair: J. Rubin (Spain)

Is the excisional margin important in breast cancer treatment?
Speaker: T. Rubo (Spain)

What minimal excisional margin in liver surgery can be accepted?
Speaker: C. Pouton (United Kingdom)

Local recurrence after radically resected pancreatic cancer - what have we missed?
Speaker: C. Verheul (Sweden)

Discussion

Monday 28 September 2015

Teaching Lecture: Radical Approach to Peritoneal Surface Malignancies using Cytoreductive Surgery
08:00 - 08:45
Chair: S. Veron (France)
Speaker: G. Gonzalez-Moreno (Spain)

Special Session: The Right Surgery for the Right Patient - Predictions & Outcomes
15:15 - 16:15
Chair: T. Creuziger (Austria)

Selection for risk reduction surgery in hereditary syndromes
Speaker: To be announced

Individualized treatment for older cancer patients
Speaker: R. A. Avis (United Kingdom)

Have guidelines improved outcomes or not?
Speaker: S. Sandrucci (Italy)

Discussion

Young Oncologists

Saturday 26 September 2015

Young Oncologists Mentorship Session 1
12:00 - 14:30
Chair: J.R. Van der Vorst (Netherlands)

Basic/Translational Research
Mentor: R. Marais (United Kingdom)

Medical Oncology
Mentor: C. Zucknick (Australia)

Radiation Oncology
Mentor: M. Baum (Germany)

Surgical Oncology
Mentor: A. Balabaud (United Kingdom)

Oncology Nursing
Mentor: A. Morales (Switzerland)

Ticketed session

Workshop: How to Avoid Burnout - Achieving Optimal Work-Life Balance
12:00 - 14:30
Coordinator: M. Struyf (Belgium)
Speaker: S. Barenaye (United Kingdom)

Special Session: Career Opportunities for Young Oncologists in Europe
15:15 - 16:15
Chair: R. Calafano (United Kingdom)

How to get the most out of a research fellowship abroad - medical oncology and lab opportunities?
Speaker: C. Mountzios (Greece)

Surgical research opportunities
Speaker: J.R. Van der Vorst (Netherlands)

Radiotherapy research opportunities
Speaker: E.C. Moser (Portugal)

Discussion

Scientific Symposium: Cancer Genetics for Oncologists - Issues in Clinical Practice
16:45 - 18:15
Chair: S. Postel-Vinay (France)
Co-Chair: J. Rodon (Spain)

Germ line genetic testing for cancer patients
Speaker: To be announced

Implementation of widespread BRCA testing - the oncologist’s perspective
Speaker: S. Barenaye (United Kingdom)

Molecular profiling of cancers - clinical utility and limitations
Speaker: N. Normanno (Italy)

What do cancer patients understand about genetic testing?
Speaker: J. Rodon (Germany)

Discussion & Roundup

Sunday 27 September 2015

Special Session: How to Improve Cancer Training and Career Planning?
11:30 - 12:30
Chair: S. Barenaye (United Kingdom)

Oncological surgical training and career plans
Speaker: S. Butler (United Kingdom)

Medical oncology training and career plans
Speaker: S. Kaliy (United Kingdom)

Discussion

Young Oncologists Mentorship Session 2
13:00 - 14:30
Chair: R. Calafano (United Kingdom)

Basic/Translational Research
Mentor: J. Rodon (Spain)

Medical Oncology
Mentor: A. Cervantes (Spain)

Radiation Oncology
Mentor: P. Wolterson (Netherlands)

Surgical Oncology

Mentor: T. de Weijhe (Netherlands)

Oncology Nursing
Mentor: J. Sharp (Sweden)

Ticketed session

Workshop: How to Break Significant News
12:00 - 14:30
Coordinator: J.R. Van der Vorst (Netherlands)
Speaker: A. Baildam (United Kingdom)

Workshop: Making the Right Oncology Career Choices for You
13:00 - 14:30
Coordinator: S. Martorell (Italy)
Speaker: F. Cardoso (Portugal)

Scientific Symposium: Genetic Testing - the oncologist’s perspective
15:00 - 16:30
Chair: S. Banerjee (United Kingdom)

Germ line genetic testing for cancer patients
Speaker: To be announced

Implementation of widespread BRCA testing - the oncologist’s perspective
Speaker: S. Barenaye (United Kingdom)

Molecular profiling of cancers - clinical utility and limitations
Speaker: N. Normanno (Italy)

What do cancer patients understand about genetic testing?
Speaker: J. Rodon (Germany)

Discussion & Roundup

Tuesday 29 September 2015

Special Session: Career Progression in Oncology
8:30 - 10:15
Chair: R. Marais (United Kingdom)

Basic/Translational Research
Mentor: R. Marais (United Kingdom)

Medical Oncology
Mentor: A. Cervantes (Spain)

Radiation Oncology
Mentor: B. Escuder (France)

Surgical Oncology
Mentor: Y. Lievens (Belgium)

Oncology Nursing
Mentor: S. Gonzalez-Moreno (Spain)

Basic/Translational Research
Mentor: C.C. Zielinski (Austria)

Medical Oncology
Mentor: R. Marais (United Kingdom)

Basic/Translational Research
Mentor: A. Baildam (United Kingdom)

Discussion & Roundup

票务会期

票务会期

票务会期
Undoubtedly, the European Cancer Congress is the must-attend event for all young oncologists in Europe in 2015.

The Congress is the leading European platform for presenting practice-changing scientific data and a unique multidisciplinary context where different areas of oncology converge to explore innovative solutions to help cancer patients. These factors combine to create the best environment to foster the professional growth of a young oncologist.

However, the European Cancer Congress traditionally does much more than that for our promising young oncologists and ECC2015 takes this tradition even further.

The programme includes a special track dedicated to young professionals in the field of oncology. This track is designed to provide advanced knowledge building a bridge between scientific progress and the clinical setting (“Cancer Genetics for Oncologists – Issues in Clinical Practice”) as well as provide deeper understanding of broader aspects of cancer care (“How to Break Significant News”).

At the same time, the Congress programme makes a point of providing invaluable mentorship opportunities for young oncology professionals. The Congress gathers in one place the most brilliant scientists and practitioners who have a strong commitment to the sharing of their experience and wisdom with the new generation of specialists. At ECC2015, young oncologists will be able to participate in special mentorship sessions designed to ensure this handover of learning acquired through a wealth of experience at the highest level of oncology practice.

Learning won’t stop there – the programme will offer sessions focused on key topics that affect every young oncologist in Europe. Experts will offer guidance on issues such as career opportunities in Europe and making the right choices among them, improving cancer training and avoiding burnout by ensuring a good work/life balance.

The Congress offers numerous networking opportunities which will help young specialists build invaluable and enduring working relationships to support their professional future.

We encourage young oncologists to register early for ECC2015 and make the most of this extraordinary career-making event!

Why take the ESMO Examination?
• Assess your knowledge in medical oncology
• Become an ESMO Certified Member
• Collect ESMO-MORCA CME points

The ESMO Examination will take place during the European Cancer Congress in Vienna with simultaneous sessions in other locations.

Register now at esmo.org

Early Registration: 16 March 2015
Late Registration: 22 July 2015

How to prepare
• Review the ESMO Examination Trial Questions online
• Access educational material online via OncologyPRO’s Tumour Knowledge Portal
• Attend the ESMO Academy, 28-30 August 2015 for an interactive, in-depth update about the major topics in oncology. Reduced fees and travel grants available for attendees pre-registered for the ESMO Examination
Patient Advocacy @ ECC2015

Developments and innovations in oncology that will lead to better outcomes can only happen by listening to patients. Without actively listening to the needs and wishes of patients, it will be impossible to fully understand and assess whether treatments are effective and this will be particularly important with the growth of personalised medicine. This is why the ECC Patient Advocacy Track Chair and experts have worked together with ECC2015 scientific track chairs to enrich the scientific programme with the patient perspective.

Patient advocates will participate in a roundtable discussion on oncology drug development in the era of genomic sequencing and will contribute their views on the evaluation of the clinical benefit of cancer drugs as well as what matters to patients in clinical trials.

The perspective of patients on survivor care will be provided in a scientific symposium looking for ways to make survivor care evidence-based for the growing number of survivors. Empowering each survivor to play a leading role in his/her own care will be a recurring theme at ECC2015. The European Cancer Congress will re-examine and shed new light on key topics for patients and survivors so that stakeholders can explore areas of collaboration particularly aimed at tackling inequalities in cancer care. A full session will look at the flow of information between healthcare professionals and patients and address topics like communication skills that facilitate shared decision making, dealing with fear both from a patient and from a healthcare professional perspective, communication on issues of sexuality and all other quality of life angles.

ECC2015 will provide educational opportunities for patient advocates so they can deepen their understanding of topics such as genetic and biomolecular testing, generics and sub-standard drugs.

Attendance scholarships covering travel and registration costs will be available to patient advocates to facilitate their participation at the European Cancer Congress.

Details will be published on www.europeancancercongress.org

Oncopolicy Forum

Unique to the European Cancer Congress is the inclusion of a track dedicated to public policy in cancer control, featuring the most pertinent issues faced by practitioners and other actors across the cancer continuum. The Oncopolicy Forum (OPF) harnesses the expertise and experience of the entire oncology community to bridge the gap between science and policy, and maximise the potential for achieving positive policy development with patient interests at the core.

The OPF has repeatedly re-affirmed itself as a unique platform for fruitful exchange between experts across the cancer continuum and decision-makers, leading to increased understanding of mutual needs and priorities towards informed policy making and tangible change.

The previous edition of the Oncopolicy Forum dealt with issues such as innovative approaches to the organisation of personalised care across Europe, facilitating personalised care for rare cancer patients through European Reference Networks, and aligning evidence and policy for the optimal prioritisation of scarce resources in oncology. High level participants included the Commissioner for Health Tonio Borg and Member of the European Parliament Teresa Riera Madurell, Rapporteur on the Horizon 2020 Programme for Research and Innovation.

This year’s OPF will once more look at the most pressing issues in oncology and how public policy can play an important role in providing cancer care professionals, researchers and patients with the political and regulatory frameworks necessary to advance patient outcomes.

On Saturday 26 September, the OPF2015 will kick-off with the first in a series of ‘Timebombs in oncology’, starting with cancer survivorship. This timebomb poses many policy challenges including how to implement effective ‘back to work’ schemes for those willing and able to return to the workplace. Cancer in the elderly will be in focus on Sunday 27 September. With the retirement age increasing in many countries, the number of people working with long-term medical conditions including certain cancers will also increase. Some employers have recognised this and are implementing workplace initiatives to address the problem. Finally, the oncology workforce will be put under the microscope on Monday 28 September and discussion with the audience will seek to solicit possible policy solutions in anticipation of workforce shortages in essential disciplines.

Inequalities in treatment outcomes - both between and within European countries - are among the other topical issues at the OPF2015. Thus, on Sunday 27 September, we will look at the current state of affairs and evaluate the multi-stakeholder effort required to ensure effective equality of access to treatment and medicines.

Another important session on Monday 28 September will unlock the possibilities for cancer research funding under the EU budget 2014 - 2020. It will enable participants to understand the sometimes complex landscape and identify the most relevant opportunities to benefit from available programmes, such as Horizon 2020. On the same day, the OPF2015 will address the critical developments on cross-border movement of cancer patients and the setting up of brand-new European Reference Networks in rare cancers.

OPF participants will have the opportunity to engage as part of an exceptional pool of multi-disciplinary cancer stakeholders – patients and professionals, to raise awareness on the issues in day-to-day oncology care, and ultimately contribute to influencing policy making in Europe.
Call for Abstracts

When to Submit

Abstract submission open: 26 January 2015
Abstract submission deadline: 28 April 2015, 21:00 Central European Time

Abstracts submitted after the stipulated deadline will not be considered. Authors are strongly advised to submit prior to the deadline and avoid unnecessary delays which may affect the standing of their abstract.

Abstract Policy and Regulations

Abstracts on case studies will be rejected.

With the submission of an abstract to European Cancer Congress 2015, the presenting author:

- Certifies to be an investigator with substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and inform co-authors of its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the European Cancer Congress 2015.
- Agrees to submit updated data for important large studies presented (in part) at previous meetings. Violation of this policy may result in rejection of the submitted abstract.
- Certifies that the information in the abstract is for exclusive presentation in the European Cancer Congress 2015 Scientific Programme and will not be presented during the ECC2015 or any Satellite Symposia.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.
- For abstracts containing clinical trial data include: Trial abbreviation, Trial Registry Number or ID background; Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), Analysis, Trial status, Trial sponsor(s).
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research and other substantive relationships.
- Releases the copyright on behalf of all authors, to ECCO and gives permission for the abstract, when selected for presentation, to be published in the European Cancer Congress 2015 Abstract book - a European Journal of Cancer Supplement (in electronic format), as well as on the ECC2015 website.
- Trials in Progress abstracts and encore presentations will not be accepted.

Abstract Selection Process

Abstracts submitted for presentation in the European Cancer Congress 2015 will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.

The following presentation formats are applicable at the European Cancer Congress 2015:

- Oral presentation
- Poster Presentation
- Poster Spotlight Sessions
- Poster Discussion
- Poster Spotlight Sessions

Abstract Withdrawal

ECCO cannot guarantee any request for withdrawal of an abstract that in any way delays the ECC2015 publications. Requests to withdraw abstracts will be accepted until 10 July 2015. After this date, abstracts selected must be presented. If the presenting author of a selected abstract cannot attend, they should assign a replacement and inform ECCO of the replacement as soon as possible.

The presenting author will receive a letter with the result of the review and the Scientific Committee’s decision on the abstract by early July.

Abstract Submission Fee

Each submitted abstract must be accompanied by a 35 EUR abstract submission fee. The submission fee can only be paid by credit card. This fee is non-refundable regardless of the final status of the abstract.

Late-Breaking Abstracts

Late-breaking abstracts describe the latest advances that will change our daily clinical practice. They should highlight novel and practice-changing studies. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Congress.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context; an early clinical trial with novel proof-of-principle data, or the demonstration of novel...
cancer biology with therapeutic implications – in each case the results should not have been fully available by the regular abstract submission deadline.

**Note:** The late-breaking abstract deadline is not an extension of regular abstract submission deadline.

**Policy & Regulation**
Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the regular abstract submission deadline will be considered.

Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.

Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.

The data in the abstract cannot be published (manuscript or abstract) prior to the Congress. With the submission of a late-breaking abstract to European Cancer Congress 2015, the presenting author must:

- Submit by the **deadline of 5 August 2015**
- Provide rationale on why the abstract should be considered as late-breaking (complete this section in the submission system).
- Ensure submission of the abstract adheres to the regular abstract submission policy and regulations in addition to the specific guidelines listed above.
- Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered.

**Embargo Policy**
Late-breaking abstracts and abstracts selected for **media** for the European Cancer Congress 2015 are embargoed until the first day of presentation. Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been presented at the ECC2015.

The first author and co-authors must not release the research/study to news media. If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.

In case of any abstract related queries please contact: abstracts@ecco-org.eu

**Abstract Topic Categories**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Sub-Topic</th>
</tr>
</thead>
</table>
| **Basic Science** | Aging and Cancer, Telomerase  
Animal Models of Cancer  
Drug Resistance and Abnormal Effects  
Cancer Cell Metabolism  
Cancer Inhibiting Cells/Cancer Stem Cells  
Cell Cycle: Cell Death, Senescence, Cell Proliferation  
DNA Damage and Repair  
Epigenetics  
Functional Genomics  
Gene Expression, Transcription/Translation  
Genomic Alterations in Cancer  
mRNA  
Oncopeptides  
Receptor and Signal Transduction  
Tumour Angiogenesis  
Tumour Immunology  
Tumour Microenvironment  
Tumour Progression: Invasion and Metastasis  
Tumour Suppressor Genes  
Viral Oncopeptides |
| **Cancer Screening and Prevention** | Primary Prevention  
Secondary Prevention  
Tertiary Prevention |
| **Central Nervous System** | Basic Science  
Multi-Modality  
Radiotherapy  
Surgery  
Systemic Therapy  
Translational Research |
| **Diagnostic/Biomarkers** | Biomarkers  
Expression Profiling  
Genetic Alteration |
| **Early Drug Development** | Angiogenic Inhibitors  
Apoptosis Inducers  
Cytokines and GSKs  
DNA Repair Mechanisms  
Drug Design  
Drug Resistance and Modifiers  
Drug Screening  
Drug Synthesis  
Formulation Research  
Monoclonal Antibodies and Targeted Drugs/Molecules  
Natural Products and Marine Compounds  
New Molecular Targets  
Radiation Interactive Agents  
Signal Transduction Modulators  
Telomerase-Targeting Agents  
Topoisomerase Inhibitors  
Toxology  
Tubulin-Interacting Agents  
Tumour Growth Inhibitors |
| **Breast Cancer - Advanced Disease** | Basic Science  
Multi-Modality  
Radiotherapy  
Surgery  
Systemic Therapy  
Translational Research |
| **Breast Cancer - Early Disease** | Basic Science  
Multi-Modality  
Radiotherapy  
Surgery  
Systemic Therapy  
Translational Research |
| **Breast Cancer - Early Disease** | Epidemiology  
Multi-Modality  
Radiotherapy  
Surgery  
Symptom Science  
Systemic Therapy |
| **Cancer in the Elderly** | Epidemiology  
Multi-Modality  
Radiotherapy  
Surgery  
Symptom Science  
Systemic Therapy |
| **Cancer in the Elderly** | General Epidemiology  
Genetic Epidemiology |
<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
<th>Topic Sub-Topic</th>
<th>Topic Sub-Topic</th>
<th>Topic Sub-Topic</th>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Malignancies - Colorectal Cancer</td>
<td>Head and Neck Cancer</td>
<td>Imaging</td>
<td>Immunotherapy of Cancer</td>
<td>Lung Cancer - Localised/Local Regional Disease</td>
</tr>
<tr>
<td>Basic Science</td>
<td>Multi-Modality</td>
<td>Basic Science</td>
<td>Radiation Therapy</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Surgery</td>
<td>Gyneaeological Cancer</td>
<td>Melanoma and Skin Cancer</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Malignancies - Noncolorectal Cancer</td>
<td></td>
<td></td>
<td></td>
<td>Lung Cancer - Metastatic Disease</td>
</tr>
<tr>
<td>Basic Science</td>
<td>Multi-Modality</td>
<td>Basic Science</td>
<td>Radiation Therapy</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Surgery</td>
<td>Gyneaeological Cancer</td>
<td>Melanoma and Skin Cancer</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genitourinary Malignancies - Nonprostate Cancer</td>
<td></td>
<td></td>
<td></td>
<td>Public Health, Health Economics, Policy</td>
</tr>
<tr>
<td>Basic Science</td>
<td>Multi-Modality</td>
<td>Basic Science</td>
<td>Radiation Therapy</td>
<td>Public Health</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Surgery</td>
<td>Gyneaeological Cancer</td>
<td>Melanoma and Skin Cancer</td>
<td></td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genitourinary Malignancies - Prostate Cancer</td>
<td></td>
<td></td>
<td></td>
<td>Supportive Care and Palliation</td>
</tr>
<tr>
<td>Basic Science</td>
<td>Multi-Modality</td>
<td>Basic Science</td>
<td>Radiation Therapy</td>
<td>Supportive Care</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Surgery</td>
<td>Gyneaeological Cancer</td>
<td>Melanoma and Skin Cancer</td>
<td></td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematological Malignancies</td>
<td></td>
<td></td>
<td></td>
<td>Surgical Oncology</td>
</tr>
<tr>
<td>Basic Science</td>
<td>Multi-Modality</td>
<td>Basic Science</td>
<td>Radiation Therapy</td>
<td>Experimental Surgical Oncology</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Surgery</td>
<td>Gyneaeological Cancer</td>
<td>Melanoma and Skin Cancer</td>
<td></td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>Translational Research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Translational Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Fellowship Grants - Application**

Fellowship grants will be made available to young oncology professionals (doctors, basic scientists, oncology nurses and radiotherapy technicians) to attend the 18th ECCO - 40th ESMO - European Cancer Congress.

ECCO member societies strongly believe in the importance of facilitating access to the Congress for young oncologists as a way to help them take their next steps towards professional excellence and best practice.

- **15 Fellowship grants** are offered to young oncology professionals from countries with lower-middle income economies as per World Bank classification.
- **10 Fellowship grants** are offered to young oncology professionals from Eastern European countries.

The following Member Societies will provide additional fellowship grants:

- EACR – 3 Fellowships (applicable to EACR members only)
- EONS – 5 Fellowships (applicable to EONS members only)
- ESMO – 3 Fellowships (applicable to ESMO members only)
- ESSO – 3 Fellowships (applicable to ESSO members only)
- SIOPE – 5 Fellowships (applicable to SIOPE members only)

Find out all you need to know on the requirements and the application process and deadlines at [www.europeancancercongress.org](http://www.europeancancercongress.org)

---

**ECCO/EJC Young Investigator’s Award**

ECCO - the European Cancer Organisation and EJC - European Journal of Cancer are pleased to announce the ECCO/EJC Young Investigator’s Award, to be presented at 18th ECCO - 40th ESMO European Cancer Congress.

The ECCO/EJC Young Investigator’s Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research. The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for recent original work in cancer research, treatment or care.

For details on the application criteria and process, visit [www.europeancancercongress.org/EJC](http://www.europeancancercongress.org/EJC)

**Deadline for applications: 5 May 2015**

Applications should be sent to Anne Blondeel, Congress Programme Coordinator via Email: anne.blondeel@ecco-org.eu

---

**Novice Research Dissemination Award for Oncology Nurses**

If this is the first time you have submitted an abstract for an international congress and you have less than five years’ experience doing research, your abstract may be considered for presentation in the ‘New Oncology Nursing Research’ session.

To be considered, you must tick the box entitled ‘Novice Research Dissemination Award’ during abstract submission. New oncology nursing researchers who tick this box and have their abstract accepted will be eligible for this new award.

All abstracts in this category will be judged by a panel, who will select 2 winners. Each award winner will receive free registration for ECC2015, and a contribution up to 1500 EUR will be reimbursed after the Congress to cover travel and accommodation.
ESTRO AWARDS

ESTRO - VARIAN AWARD

A prize of 2,500 euros will be given to a radiation oncology professional for research in the field of radiobiology, radiation physics, clinical radiotherapy or radiation technology.

CRITERIA FOR ELIGIBILITY
1. Candidates should be ESTRO members, having completed the submitted work in the previous year.
2. Submissions should be brought forward by the candidates or their department heads and may be work done as an individual piece of research or as a thesis complete in the field of biological, physical and clinical research.
3. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.
4. Candidates should submit:
   - A curriculum vitae and a list of publications
   - A copy of the abstract on the project which should have been submitted for the European Cancer Congress (indicate abstract title and submitting author with your application)
   - An English summary of their work (max 2 pages).

APPLICATIONS FOR THE ABOVE LISTED AWARDS ARE TO BE ADDRESSED TO:
Eralda Azizaj
ESTRO Programme Manager
Rue Martin V 40, 1200 Brussels, Belgium
Tel. +32 2 775 93 40
E-mail: eralda.azizaj@estro.org
Deadline for submission: 1 April 2015

ESTRO - ACCURAY AWARD

A prize of 2,500 euros will be given to a radiation oncology professional for research in the field of “High Precision Radiotherapy”. Awardees may be qualified in the field of clinical radiotherapy, radiation physics, radiation technology or radiobiology.

CRITERIA FOR ELIGIBILITY
1. Candidates should be ESTRO Members, having completed the submitted work in the previous or current year.
2. Submissions should be brought forward by the candidates and may be work done as an individual piece of research or as a thesis completed in the field of biological, physical or clinical research.
3. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.
4. Candidates should submit:
   - A curriculum vitae and a list of publications
   - A copy of the abstract on the project which should have been submitted for the European Cancer Congress (indicate abstract title and submitting author with your application)
   - An English summary of their work (max 2 pages).

What do oncologists need?
Reliable, trusted research and answers fast!
Make an impact! Get your research read worldwide.

European Journal of Cancer (EJC)
- The official journal of the EORTC, ECCO, the EACR and EUSOMA
- Editor-in-Chief: Alexander M.M. Eggermont, Villejuif, France
- Impact Factor: 4.819
  JCR, Thomson Reuters 2013
- Available to read on your mobile and your iPad
- More than 1.2 million articles downloaded worldwide each year
- Open access publishing options available

Stay well-informed, don’t miss a thing
Get monthly eTOCs and updates free: ejcancer.com

Ad page ECCO Programme book - ESTRO Awards3.indd 1
18/11/14 17:15
Publish with The Lancet Oncology, the global leader in clinical oncology, and open your research to the eyes and minds of oncologists around the world.

The Lancet Oncology has a global online audience of 16 million researchers, clinicians, and academics across 170 countries, who this year alone accessed more than 1 million articles from our online platforms; the journal is also free online to all low-to-middle income HINARI countries.

In fact, more than 11,000 oncologists in North America and over 5000 in Europe and Asia receive the full print journal. Key articles are featured in more than 3000 news stories annually and nearly 50,000 oncologists receive our e-alert announcements.

Ensure your research has an immediate and far-reaching impact. Publish with us and make a difference in the world of clinical oncology.

Global readership with an immediate and far-reaching impact

The European Cancer Congress 2015

GROUND-BREAKING RESEARCH TRANSFORMING MODERN ONCOLOGY

- Showcase your work at this unique multidisciplinary oncology platform
- Gain cutting-edge knowledge from a wealth of sessions tailored to your research interests:
  - A dedicated EACR society session
  - A Scientific Symposium on the Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer, chaired by A. Børresen-Dale
  - A Scientific Symposium on the Mechanisms of Resistance to Targeted Therapies, chaired by R. Marais
  - An Integrated Session on Immunotherapy in the Management of Metastatic Melanoma, chaired by A. M. M. Eggermont

Full details on: www.europeancancercongress.org

Special rates for EACR members

Abstract submission deadline: 28 April 2015
In 2015, the thirty fifth Congress of the European Society of Surgical Oncology will take place within the multidisciplinary programme of the ECC2015.

Once again, ESSO has joined forces with the other founding members of ECCO—the European Cancer Organisation to offer an exciting scientific programme promoting multidisciplinarity.

The ECC2015 scientific programme will also feature a strong surgical oncology track throughout the meeting covering all aspects of the investigation and treatment of the common solid cancers that form the workload of cancer surgeons.

**Highlights of the surgical track include:**

- Special Session on Excisional Margins in 2015
- Special Session on The Right Surgery for the Right Patient: Predictions & Outcomes
- Special Session on Highly Skilled Surgery and Patients Outcomes
- Teaching Lecture on Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Teaching Lecture on Surgery in Synchronous Oligometastatic Disease
- Scientific Symposium on Neoadjuvant Treatment - When Is It of Benefit for the Patient and Doctor
- Society Award Session on Education in Cancer Surgery

**Don’t miss the opportunity to take part in the largest oncology congress in Europe!**

- Submit an abstract and deliver your surgical messages to the largest multidisciplinary audience in Europe.
- Learn from leaders in the field of oncology and widen your network of peers.
- Take advantage of the significant discounted rates for ESSO members!

---

**Why You Should Participate at ECC2015**

- **Largest European Cancer Platform:**
  In 2015, the 18th ECCO – 40th ESMO European Cancer Congress (ECC2015) is the largest European multidisciplinary oncology platform for all oncology stakeholders to meet, learn and discuss new ground breaking data and share best practice to provide each cancer patient with optimal treatment and care.

- **Impressive number of late-breaking abstracts presentations:**
  The European Cancer Congress is renowned for attracting and presenting a remarkable number of practice changing abstracts.

- **Global Impact:**
  The abundance of practice-changing data presented at the European Cancer Congress is widely disseminated to a global readership thanks to our worldwide media coverage generated by the hundreds of journalists attending or reporting on the Congress.

- **Unique Multidisciplinary Approach:**
  We have designed more integrated sessions bringing about dialogue and debate in overlapping areas of scientific research. The programme is therefore more streamlined, with fewer tracks, facilitating an even more productive experience for delegates.

- **Oncopolicy:**
  The European Cancer Congress remains the only European cancer meeting with a dedicated Oncopolicy forum. The Oncopolicy Forum in Amsterdam tackled topics including research, personalised medicine and care, organisation of specialised care, and translation of evidence into policy. The recommendations derived from these discussions will be revisited at the Oncopolicy Forum in Vienna in 2015.

- **Vienna, Trailblazer in Medicine – Host City:**
  Vienna is a natural host of ECC2015. Its track record as a leader in medical thought and practice speaks for itself – it has made its mark in key areas like radiotherapy, clinical diagnosis and public health to name a few.

More information on [www.essoweb.org/events/ESSO35](http://www.essoweb.org/events/ESSO35)
OncologyAdvance

Where cancer researchers and oncologists find the latest peer-reviewed research and reviews.

A convenient one-stop resource that:
- announces latest Articles-in-Press from Elsevier’s comprehensive portfolio of Oncology journals
- provides access to the new editions and archive of the EJC News Focus updates
- transmits free Podcasts from leading publications
- keeps you informed on industry meetings and events
- and much more...

Visit OncologyAdvance.com today.

ONE CLICK ACCESS TO ESSENTIAL RESOURCES IN ONCOLOGY
Call for Nominations

ECCO – the European CanCer Organisation and the Pezcoller Foundation are pleased to announce the Call for Nominations for the 2015 Pezcoller Foundation-ECCO Recognition for Contribution to Oncology.

For 2015, in collaboration with ECCO – The European CanCer Organisation, the Pezcoller Foundation-ECCO Recognition for Contribution to Oncology will be awarded to a single individual for his/her professional life dedication to the improvement of cancer treatment, care and research. The award is open to all professions and specialties within the oncology field.

Nominations will be accepted for candidates irrespective of race, gender or nationality. Institutions, groups or associations are not eligible. Self-nominations will not be considered.

Candidates must be nominated on the official form by one who is, or has been, affiliated with a university or medical institution. A curriculum vitae and description of the candidate’s professional contribution to the field of oncology should be included with the application form.

Nominators are requested to keep their nomination confidential and to refrain from informing the nominee. The awardee will be selected by an International Committee appointed by the ECCO President with the agreement of the Council of the Pezcoller Foundation. The decision concerning the 2015 winner will be taken in April 2015.

The award consists of a prize of 30,000 EUR and a commemorative plaque. The Award Ceremonies will be held in Rovereto (Italy), on 11 September 2015 and in Vienna, during the 18th ECCO – 40th ESMO – European Cancer Congress as a Plenary Lecture to be delivered during the Presidential Session of Sunday 27 September 2015.
We take cancer personally

Patients are at the heart of everything we do at Roche. They motivate and inspire us to search for and develop innovative medicines and therapeutic solutions with the goal of transforming the lives of people with cancer around the globe.

We’ve come a long way, but there’s still a long way to go.
### Registration Fees

<table>
<thead>
<tr>
<th>Rate</th>
<th>Deadline</th>
<th>ECC 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early Rate</strong></td>
<td><strong>Tuesday 9 April 2015</strong></td>
<td></td>
</tr>
<tr>
<td>Early Rate Members</td>
<td></td>
<td>380</td>
</tr>
<tr>
<td>Early Rate Non Members</td>
<td></td>
<td>699</td>
</tr>
<tr>
<td>Early Rate Groups</td>
<td></td>
<td>699</td>
</tr>
<tr>
<td>Early Rate Junior Participants</td>
<td></td>
<td>175</td>
</tr>
<tr>
<td>Early Rate Emerging Economy</td>
<td></td>
<td>130</td>
</tr>
<tr>
<td>Early Rate Nurses Members</td>
<td></td>
<td>210</td>
</tr>
<tr>
<td>Early Rate Nurses Non-Members</td>
<td></td>
<td>375</td>
</tr>
<tr>
<td>Early Rate Patient Advocates</td>
<td></td>
<td>125</td>
</tr>
<tr>
<td><strong>Regular Rate</strong></td>
<td><strong>Tuesday 4 August 2015</strong></td>
<td></td>
</tr>
<tr>
<td>Regular Rate Members</td>
<td></td>
<td>699</td>
</tr>
<tr>
<td>Regular Rate Non Members</td>
<td></td>
<td>999</td>
</tr>
<tr>
<td>Regular Rate Groups</td>
<td></td>
<td>999</td>
</tr>
<tr>
<td>Regular Rate Junior Participants</td>
<td></td>
<td>199</td>
</tr>
<tr>
<td>Regular Rate Emerging Economy</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Regular Rate Nurses Members</td>
<td></td>
<td>355</td>
</tr>
<tr>
<td>Regular Rate Nurses Non-Members</td>
<td></td>
<td>485</td>
</tr>
<tr>
<td>Regular Rate Patient Advocates</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td><strong>Late Rate</strong></td>
<td><strong>Friday 18 September 2015</strong></td>
<td></td>
</tr>
<tr>
<td>Late Rate Members</td>
<td></td>
<td>999</td>
</tr>
<tr>
<td>Late Rate Non Members</td>
<td></td>
<td>1099</td>
</tr>
<tr>
<td>Late Rate Junior Participants</td>
<td></td>
<td>220</td>
</tr>
<tr>
<td>Late Rate Emerging Economy</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Late Rate Nurses Members</td>
<td></td>
<td>460</td>
</tr>
<tr>
<td>Late Rate Nurses Non-Members</td>
<td></td>
<td>585</td>
</tr>
<tr>
<td>Late Rate Patient Advocates</td>
<td></td>
<td>170</td>
</tr>
<tr>
<td><strong>Onsite Rate</strong></td>
<td>As of 19 September 2015</td>
<td></td>
</tr>
<tr>
<td>Onsite Rate Members/Non Members</td>
<td></td>
<td>1199</td>
</tr>
<tr>
<td>Onsite Rate Nurses Members/Non Members</td>
<td></td>
<td>685</td>
</tr>
<tr>
<td>Onsite Rate Junior Participants</td>
<td></td>
<td>235</td>
</tr>
<tr>
<td>Onsite Rate Patient Advocates</td>
<td></td>
<td>190</td>
</tr>
<tr>
<td>Day rate</td>
<td></td>
<td>355</td>
</tr>
</tbody>
</table>
Exhibition & Sponsorship Opportunities

Showcase your latest scientific data through this uniquely powerful platform of European and global oncology science and clinical practice.

ECC2015 offers you a wide range of opportunities to achieve the highest level of exposure to a multidisciplinary audience from Europe and around the world.

A vast majority of Congress participants spends time in the Exhibition Hall with an overwhelming number expressly seeking product and technology updates.

The Congress provides you opportunities of proven effectiveness like Satellite Symposia, Exhibitor Spotlight Sessions and many others.

We look forward to working with you to identify and secure the items best suited to your objectives for your participation in ECC2015.

We look forward to greeting you in Vienna!

For information on sponsorship and exhibition opportunities, please contact:
Bruno De Man
Phone: +32 2 775 02 04
Email: bruno.deman@ecco-org.eu

To download the Invitation to Industry brochure and view the exhibition floor plan please visit the ECC2015 website at: www.europeancancercongress.org

General Information

Accommodation

Mondial Congress & Events has been appointed as the official local housing partner for the 18th ECCO – 40th ESMO European Cancer Congress and is offering hotel accommodation and other services for both groups and individuals.

Booking Accommodation for individuals are open since 1 October, 2014.

For all accommodation queries and information, please contact:

Mondial Congress & Events
Operngasse 20b
1040 Vienna, Austria
Tel: +43 1 58804 0
Fax: +43 1 58804 185
E-mail: ECC2015@mondial-congress.com

We kindly ask you to contact the appointed local housing partner directly. The Congress secretariat cannot provide accommodation-related information or handle any such related requests.

Congress Update Service

The Congress Update Service is the official electronic newsletter of the European Cancer Congress. It is specifically designed to share with you essential updates and notable developments in the lead up to the Congress.

Launching six months in advance, this monthly newsletter is sent to all registrants.

Please visit the website if you wish to subscribe:
www.europeancancercongress.org

ECCO and its Founding Members

As founding members of ECCO - the European CanCer Organisation - ESMO, ESTRO, ESSO, EACR, EONS and SIOPE have joined forces once again to create a powerful platform promoting multidisciplinarity. These organisations support a multidisciplinary approach as the ultimate way to ensure the best outcomes and quality of life for all cancer patients.
ECC2015 gives you the opportunity to:

- Join Society Sessions (see programme for full details)
- Attend Society General Assemblies (see programme for full details)
- Meet Society Secretariats at their exhibition stands
- Fast-track your Society membership application and renewal at each Society’s stand
- Network in a friendly professional environment and discuss in comfort all the exciting developments at ECC2015 — all in your Society’s Exclusive Member Lounge

Insurance

The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.

Language and Translation

The official language of the Congress is English. No simultaneous translation will be provided.

Lunch and Refreshments

Lunch or refreshments are not included as part of the registration fee.

Official Carrier

Save up to 20% on travel with the Star Alliance network

The Star Alliance™ member airlines have been appointed as the Official Airline Network for the 18th ECCO – 40th ESMO European Cancer Congress, Vienna, 25 – 29 September 2015.

Registered participants travelling to the event may qualify for a Star Alliance Conventions Plus discount of up to 20%, depending on fare and class of travel booked. To obtain the discount, please quote the event code: OS13S15 when calling the reservation office of a participating Star Alliance member airline.

For booking office information please visit:

www.staralliance.com/conventionsplus

The participating airlines for this event will be announced soon on the Congress website:

www.europeancancercongress.org

Discounts are offered on most published business and economy class fares, excluding website/internet fares, senior and youth fares, group fares and Round the World fares.

Please note: For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.

Networking at ECC2015

Meeting peers from a variety of disciplines and from all around the world is at the heart of the ECC2015 experience. The Congress will provide a variety of opportunities for delegates to interact, exchange ideas and share best practice. The Congress Update Service newsletter will provide more detailed information closer to the meeting.

Informal Networking Event

Take this opportunity to meet colleagues from all over the world in a relaxed, friendly environment. The Congress Informal Networking Event will take place on Monday 28 September as of 20:30 at the Volksgarten Clubdiskothek, Burgring, A-1010 Vienna. Tickets can be purchased for 65 EUR at the time of registration or onsite at the Congress (subject to availability).

Transportation

With their Congress badges, delegates can travel for free with Vienna’s public transport system (25-29 September 2015). The Congress Centre Messe Wien is easy to reach both by public transportation and by car. It is conveniently located within just 10 minutes from Vienna’s city centre.

Messe Wien is well served by underground: line U2, station ‘Messe-Prater’, and by bus: lines 11A and 80B.

To reach Messe Wien by car, please use GPS destination 1020 Vienna, Ausstellungsstraße or Trabrennstraße.
BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC
WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to the European Cancer Congress 2015 in Vienna, Austria.

And with over 18,500 flights a day to 1,316 destinations across 192 countries, our 27 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code OS13S15 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 27 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus

For more than five decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches that accelerate the pace and progress of cancer care.

To learn more, please visit www.lillyoncology.com
Some tumor cells can evade the body’s immune response, which may result in disease progression²,³

- One function of the body’s immune response is to detect and destroy tumor cells through activated T cells and other mechanisms; tumor cells express multiple antigens that are not expressed in normal tissue.¹⁻³
- However, some tumor cells may evade the body’s immune response by exploiting the PD-1 checkpoint pathway through expression of the dual PD-1 ligands PD-L1 and PD-L2.¹,²,⁴⁻⁷
- PD-L1 and PD-L2 engage the PD-1 receptor on T cells in order to inactivate T cells, which may allow tumor cells to evade the immune response.¹,²,⁸

MSD is committed to furthering the understanding of immunology in cancer, including the role of the PD-1 pathway.

Visit the MSD booth to learn more.